<SEC-DOCUMENT>0001193125-22-289176.txt : 20221121
<SEC-HEADER>0001193125-22-289176.hdr.sgml : 20221121
<ACCEPTANCE-DATETIME>20221118173930
ACCESSION NUMBER:		0001193125-22-289176
CONFORMED SUBMISSION TYPE:	F-1
PUBLIC DOCUMENT COUNT:		9
FILED AS OF DATE:		20221121
DATE AS OF CHANGE:		20221118

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Virax Biolabs Group Ltd
		CENTRAL INDEX KEY:			0001885827
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		F-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-268486
		FILM NUMBER:		221402988

	BUSINESS ADDRESS:	
		STREET 1:		30 BROADWICK STREET
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1F 8LX
		BUSINESS PHONE:		44 020 7788 7414

	MAIL ADDRESS:	
		STREET 1:		30 BROADWICK STREET
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1F 8LX

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Virax Biolabs (Cayman) Ltd
		DATE OF NAME CHANGE:	20210930
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1
<SEQUENCE>1
<FILENAME>d423556df1.htm
<DESCRIPTION>F-1
<TEXT>
<HTML><HEAD>
<TITLE>F-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on November&nbsp;18, 2022. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration Statement
<FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">F-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Virax Biolabs Group Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of Registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not
Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Cayman Islands</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2835</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction of<BR>incorporation or organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Primary Standard Industrial<BR>Classification Code Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification Number)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>30 Broadwick Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>London, W1F 8LX </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>United
Kingdom </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Telephone: +44 020 7788 7414 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of Registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Virax Biolabs USA Management, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>23501 Cinco Ranch Blvd. Ste <FONT STYLE="white-space:nowrap">H120-289</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Katy, TX 77494 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>+44 020
7788 7414 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies of all communications, including communications sent to agent for service, should be sent to: </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Lawrence S. Venick, Esq. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Loeb&nbsp;&amp; Loeb LLP </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2206-19</FONT> Jardine House </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1 Connaught Place, Central </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Hong Kong SAR </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Telephone:
<FONT STYLE="white-space:nowrap">+852-3923-1111</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Fax: <FONT STYLE="white-space:nowrap">+852-3923-1100</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to public: </B>As soon as practicable after this Registration Statement becomes
effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933, as amended, check the following box.&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the
Securities Act: Emerging growth company&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an emerging growth company that prepares its financial statements in
accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#134; provided pursuant to Section&nbsp;7(a)(2)(B) of the
Securities Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration
statement shall become effective on such date as the Commission, acting pursuant to such Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The term &#147;new or revised financial accounting standard&#148; refers to any update issued by the Financial
Accounting Standards Board to its Accounting Standards Codification after April&nbsp;5, 2012. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this preliminary prospectus is not complete and may be changed. We
may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting offers to buy these
securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT COLOR="#ff4338"><B>PRELIMINARY PROSPECTUS (SUBJECT TO COMPLETION)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT COLOR="#ff4338"><B>DATED&nbsp;NOVEMBER&nbsp;18,&nbsp;2022</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>5,825,000 Ordinary Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g423556g03s01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Virax Biolabs Group Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the resale by the selling shareholders named in this prospectus from time to time of up to 5,825,000<B> </B>of our
ordinary shares, par value $0.0001 per share (the &#147;Ordinary Shares&#148;). These 5,825,000<B> </B>Ordinary Shares consist of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,165,000 Ordinary Shares (the &#147;PIPE Shares&#148;) issued pursuant to the securities purchase agreement,
dated as of November&nbsp;3, 2022, by and between Armistice Capital Master Fund Ltd. (the &#147;PIPE Securities Purchase Agreement&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,165,000 Ordinary Shares (the <FONT STYLE="white-space:nowrap">&#147;Pre-Funded</FONT> Warrant Shares&#148;)
issued or issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (the <FONT STYLE="white-space:nowrap">&#147;Pre-Funded</FONT> Warrants&#148;) that were issued pursuant to the PIPE Securities Purchase Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,495,000 Ordinary Shares (the &#147;Warrant Shares&#148;) issued or issuable upon the exercise of ordinary
warrants (the &#147;Ordinary Warrants&#148;) that were issued pursuant to the PIPE Securities Purchase Agreement; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among
other things, (i)&nbsp;each Ordinary Warrant is exercisable for $1.73 per ordinary share and has a term of 5.5 years from the issuance date and (ii)&nbsp;each <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant is exercisable for $0.0001 per
ordinary share and expires upon the exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant. If at the time of exercise there is no effective registration statement registering, or the prospectus contained therein is not available
for the issuance of the ordinary shares underlying the <FONT STYLE="white-space:nowrap">Pre-Warrants</FONT> to the holder, the holder may, in its sole discretion, elect to exercise the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant
through a cashless exercise, in which case the holder would receive upon such exercise the net number of ordinary shares determined according to the formula set forth in the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant, as applicable.
The holder of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant may, in its sole discretion, elect to exercise the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant through a cashless exercise, in which case the holder would
receive upon such exercise the net number of ordinary shares determined according to the formula set forth in the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant, as applicable. If the Company does not issue the ordinary shares in a
timely fashion, the Warrant and the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant each contain certain damages provisions. A holder will not have the right to exercise any portion of (i)&nbsp;the Warrant if the holder (together with its
affiliates) would beneficially own in excess of 4.99% of the number of the Company&#146;s ordinary shares outstanding immediately after giving effect to the exercise or (ii)&nbsp;the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant if the
holder (together with its affiliates) would beneficially own in excess of 9.99%, in each case as such percentage of beneficial ownership is determined in accordance with the terms of the Ordinary Warrants and the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, as applicable. However, any holder may increase or decrease such percentage, but not in excess of 9.99%, provided that any increase will not be effective until the 61st day after such
election. The exercise price of the Warrants is subject to appropriate adjustment in the event of certain share dividends and distributions, share splits, reclassifications or similar events affecting our ordinary shares and also upon any
distributions of assets, including cash, stock or other property to our shareholders. If a fundamental transaction occurs, then the successor entity will succeed to, and be substituted for us, and may exercise every right and power that we may
exercise and will assume all of our obligations under the Warrants and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants with the same effect as if such successor entity had been named in the Warrant and the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants itself. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our registration of the Ordinary Shares covered by this prospectus does not mean that the
selling shareholder will offer or sell any of such Ordinary Shares. The selling shareholders named in this prospectus, or their donees, pledgees, transferees or other
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest,</FONT></FONT> may resell the Ordinary Shares covered by this prospectus through public or private transactions at prevailing market prices, at prices related
to prevailing market prices or at privately negotiated prices. For additional information on the possible methods of sale that may be used by the selling shareholder, you should refer to the section of this prospectus entitled &#147;Plan of
Distribution.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not receive any of the proceeds from the sale of ordinary shares by the selling shareholders. However, we
will receive proceeds from the exercise of the Warrants, if such securities are exercised for cash. We intend to use those proceeds, if any, for general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Ordinary Shares subject to resale hereunder will have been issued by us and acquired by the selling shareholders prior to any resale of
such shares pursuant to this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No underwriter or other person has been engaged to facilitate the sale of the Ordinary Shares in
this offering. We will bear all costs, expenses and fees in connection with the registration of the ordinary shares. The selling shareholders will bear all commissions and discounts, if any, attributable to their respective sales of our ordinary
shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ordinary shares is traded on The Nasdaq Capital Market under the symbol &#147;VRAX.&#148; On November&nbsp;18, 2022, the
reported sales price of our Ordinary Shares on The Nasdaq Capital Market was $1.41 per share. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investment
in our Ordinary Shares involves a high degree of risk. See &#147;</B><B><I><A HREF="#rom423556_4">Risk Factors</A></I></B><B>&#148; beginning on page 15, in our periodic reports filed from time to time with the Securities and Exchange Commission,
which are incorporated by reference in this prospectus and in any applicable prospectus supplement. You should carefully read this prospectus and the accompanying prospectus supplement, together with the documents we incorporate by reference, before
you invest in our ordinary shares. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are both an &#147;emerging growth company&#148; and a &#147;foreign private issuer&#148; as
defined under the U.S. federal securities laws and, as such, may elect to comply with certain reduced public company reporting requirements for this and future filings. See &#147;Prospectus Summary &#151; Implications of Being an Emerging Growth
Company and a Foreign Private Issuer&#148; for additional information. Investors are cautioned that you are buying shares of a shell company issuer incorporated in the Cayman Islands with operating subsidiaries in Singapore, China, Hong Kong and
British Virgin Islands, investors will not hold direct equity investments in our China and Hong Kong operating subsidiaries. Our ordinary shares offered in this prospectus are shares of our Cayman Islands holding company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our Ordinary Shares is highly speculative and involves a significant degree of risk. Virax Biolabs Group Limited, which we refer
to as &#147;Virax Cayman&#148;, is a holding company incorporated as an exempted company under the laws of the Cayman Islands. As a holding company with no material operations of our own, Virax Cayman conduct a substantial majority of our sales and
trading activities through our operating entity established in Singapore, Virax Biolabs Pte. Limited, which we refer to as SingaporeCo. Currently, Virax Cayman indirectly owns 95.65% of the equity interests in SingaporeCo. However, some of Virax
Cayman&#146;s operations are currently conducted through our operating entities established in the British Virgin Islands, Hong Kong and Shanghai, primarily, Logico Bioproducts Corp., Virax Immune <FONT STYLE="white-space:nowrap">T-Cell</FONT>
Medical Device Company Limited and Shanghai Xitu Consulting Co., Limited, which we refer to as Logico BVI, Virax Immune <FONT STYLE="white-space:nowrap">T-Cell</FONT> and Shanghai Xitu, respectively. Our ordinary shares offered in this prospectus
are shares of our Cayman Islands holding company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent statements by the Chinese government have indicated an intent to exert more
oversight and control over offerings that are conducted overseas and/or foreign investments in China based issuers. Any future action by the Chinese government expanding the categories of industries and companies whose foreign securities offerings
are subject to government review could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and could cause the value of such securities to significantly decline or be worthless. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recently, the PRC government initiated a series of regulatory actions and made a number of public statements on the regulation of business
operations in China with little advance notice, including cracking down on illegal activities in the securities market, enhancing supervision over China-based companies listed overseas using a variable interest entity structure, adopting new
measures to extend the scope of cybersecurity reviews, and expanding efforts in anti-monopoly enforcement. We are not subject to these regulatory actions or statements, as we do not have a </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
variable interest entity structure and our business does not involve the collection of user data, implicate cybersecurity, or involve any other type of restricted industry. Because these
statements and regulatory actions are new, however, it is highly uncertain how soon legislative or administrative regulation making bodies in China will respond to them, or what existing or new laws or regulations will be modified or promulgated, if
any, or the potential impact such modified or new laws and regulations will have on our daily business operations or our ability to accept foreign investments and list on an U.S. exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Holding Foreign Companies Accountable Act, or the HFCA Act, was enacted on December&nbsp;18, 2020. In accordance with the HFCA Act,
trading in securities of any registrant on a national securities exchange or in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> trading market in the United States may be prohibited if the Public
Company Accounting Oversight Board (the &#147;PCAOB&#148;) determines that it cannot inspect or fully investigate the registrant&#146;s auditor for three consecutive years beginning in 2021, and, as a result, an exchange may determine to delist the
securities of such registrant. On June&nbsp;22, 2021, the U.S. Senate passed the Accelerating Holding Foreign Companies Accountable Act, which, if enacted, would amend the HFCA Act and require the SEC to prohibit an issuer&#146;s securities from
trading on any U.S. stock exchanges if its auditor is not subject to PCAOB inspections for two consecutive years instead of three, thus reducing the time period before our securities may be prohibited from trading or delisted if our auditor is
unable to meet the PCAOB inspection requirement. Pursuant to the HFCA Act, the PCAOB issued a Determination Report on December&nbsp;16, 2021 which found that the PCAOB is unable to inspect or investigate completely registered public accounting firms
headquartered in: (1)&nbsp;mainland China of the People&#146;s Republic of China because of a position taken by one or more authorities in mainland China; and (2)&nbsp;Hong Kong, a Special Administrative Region and dependency of the PRC, because of
a position taken by one or more authorities in Hong Kong. In addition, the PCAOB&#146;s report identified the specific registered public accounting firms which are subject to these determinations. On August&nbsp;26, 2022, the PCAOB entered into a
Statement of Protocol with the China Securities Regulatory Commission and the Ministry of Finance of the PRC and, as summarized in the &#147;Statement on Agreement Governing Inspections and Investigations of Audit Firms Based in China and Hong
Kong&#148; published on the U.S. Securities and Exchange Commission&#146;s official website, the parties agreed to the following: (i)&nbsp;in accordance with the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, the PCAOB shall have independent
discretion to select any issuer audits for inspection or investigation; (ii)&nbsp;the PCAOB shall have direct access to interview or take testimony from all personnel of the audit firms whose issuer engagements are being inspected or investigated;
(iii)&nbsp;the PCAOB shall have the unfettered ability to transfer information to the SEC, in accordance with the Sarbanes-Oxley Act; and (iv)&nbsp;the PCAOB inspectors shall have access to complete audit work papers without any redactions, with
view-only procedures for certain targeted pieces of information such as personally identifiable information. Our registered public accounting firm, BF Borgers CPA PC, is not headquartered in mainland China or Hong Kong and was not identified in this
report as a firm subject to the PCAOB&#146;s determination. Notwithstanding the foregoing, if the PCAOB is not able to fully conduct inspections of our auditor&#146;s work papers in China, you may be deprived of the benefits of such inspection which
could result in limitation or restriction to our access to the U.S. capital markets and trading of our securities may be prohibited under the HFCA Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within the organization, investor cash inflows have all been received by Virax Cayman. Cash to fund Virax Cayman&#146;s operations is
transferred from Virax Cayman down through our Singapore, Hong Kong, BVI entities and then into our Chinese entity through capital contributions and loans. However, the PRC government imposes controls on the convertibility of RMB into foreign
currencies and, in certain cases, the remittance of currency out of China, and investment in Chinese companies, which are governed by the Foreign Investment Law and Company Law, and the dividends and distributions from Shanghai Xitu is subject to
relevant regulations and restrictions on dividends and payment to parties outside of China. Transfers among our Singapore and Hong Kong entities are not restricted under Singapore and Hong Kong Laws. No dividends or distribution have been made by
our subsidiaries or by Virax Cayman to date and we intend to reinvest all cash into our subsidiaries for the foreseeable future. For the years ended March&nbsp;31, 2022 and 2021,there was no transfer between Virax Cayman and its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or the accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom423556_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom423556_2">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom423556_3">The Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom423556_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom423556_5">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom423556_6">Market, Industry and Other Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom423556_7">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom423556_8">Description of Share Capital and Governing Documents</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom423556_9">Selling Shareholder</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom423556_10">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom423556_11">Expenses Related to this Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom423556_12">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom423556_13">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom423556_14">Incorporation of Certain Information by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom423556_15">Enforcement of Civil Liabilities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom423556_16">Where You Can Find Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom423556_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of the registration statement that we filed with the Securities and Exchange Commission (the &#147;SEC&#148;) pursuant
to which the selling shareholders named herein may, from time to time, offer and sell or otherwise dispose of the ordinary shares covered by this prospectus. As permitted by the rules and regulations of the SEC, the registration statement filed by
us includes additional information not contained in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference into
this prospectus include important information about us, the securities being offered and other information you should know before investing in our securities. You should not assume that the information contained in this prospectus is accurate on any
date subsequent to the date set forth on the front cover of this prospectus or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this
prospectus is delivered or shares of ordinary shares are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in this prospectus, including the documents incorporated by reference
therein, in making your investment decision. You should also read and consider the information in the documents to which we have referred you under &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by
Reference&#148; in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on this prospectus and the information incorporated or deemed to be incorporated
by reference in this prospectus. We have not, and the selling shareholders have not, authorized anyone to give any information or to make any representation to you other than those contained or incorporated by reference in this prospectus. If anyone
provides you with different or inconsistent information, you should not rely on it. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to
make such offer or solicitation in such jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We further note that the representations, warranties and covenants made by us in
any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the
parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations,
warranties and covenants should not be relied on as accurately representing the current state of our affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated,
information contained or incorporated by reference in this prospectus concerning our industry, including our general expectations and market opportunity, is based on information from our own management estimates and research, as well as from
industry and general publications and research, surveys and studies conducted by third parties. Management estimates are derived from publicly available information, our knowledge of our industry and assumptions based on such information and
knowledge, which we believe to be reasonable. In addition, assumptions and estimates of our and our industry&#146;s future performance are necessarily uncertain due to a variety of factors, including those described in &#147;Risk Factors&#148;
beginning on page 15 of this prospectus. These and other factors could cause our future performance to differ materially from our assumptions and estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>For investors outside the United States: We have not done anything that would permit the offering or possession or distribution of this
prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions
relating to, the offering of the securities described herein and the distribution of this prospectus outside the United States. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Our financial statements are prepared and presented in accordance with international financial reporting standards (&#147;IFRS&#148;). Our
historical results do not necessarily indicate our expected results for any future periods. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we explicitly state otherwise or
the context otherwise indicates clearly, all references in this proxy statement to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; or &#147;our Group&#148; refer to Virax Biolabs Group Limited and its subsidiaries, namely, Virax Biolabs (UK)
Limited, Virax Biolabs USA Management, Inc., Virax Biolabs Limited, Virax Immune <FONT STYLE="white-space:nowrap">T-Cell</FONT> Medical Device Company Limited, Virax Biolabs Pte. Limited, Logico Bioproducts Corp., and Shanghai Xitu Consulting Co.,
Limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The &#147;Company&#148; or &#147;Virax Cayman&#148; refers to Virax Biolabs Group Limited.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;GBP&#148; or &#147;GB&pound;&#148; refers to the legal currency of the United Kingdom. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;HKD&#148; or &#147;HK$&#148; refers to the legal currency of Hong Kong. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;RMB&#148; or &#147;Renminbi&#148; refers to the legal currency of China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;IVD&#148; refers to <FONT STYLE="white-space:nowrap">in-vitro</FONT> diagnostics<B><I>.</I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;PRC&#148; or &#147;China&#148; refers to the People&#146;s Republic of China, including Hong Kong and Macau. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Prospectus&#148; refers to the public offering prospectus unless we explicitly state otherwise or the context otherwise indicates
clearly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;SGD&#148; or &#147;S$&#148; refers to the legal currency of Singapore. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;United Kingdom&#148; or &#147;UK&#148; refers to the England, Scotland, Wales and Northern Ireland for the purpose of this prospectus.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;$&#148; or &#147;U.S. dollars&#148; or &#147;USD&#148; refers to the legal currency of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have made rounding adjustments to some of the figures included in this prospectus. Accordingly, numerical figures shown as totals in some
tables may not be an arithmetic aggregation of the figures that preceded them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, all information in
this prospectus assumes no exercise by the underwriters of their over-allotment option and no exercise of the Underwriter Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
business is primarily conducted in Europe, and the financial records of our subsidiaries in Asia are maintained in USD, and our functional currency is USD. Our consolidated financial statements are presented in U.S. dollars. We use U.S. dollars as
the reporting currency in our consolidated financial statements and in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom423556_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary provides an overview of selected information contained elsewhere or incorporated by reference in this prospectus and does not contain all of
the information you should consider before investing in our securities. You should carefully read the prospectus, the information incorporated by reference and the registration statement of which this prospectus is a part in their entirety before
investing in our securities, including the information discussed under &#147;Risk Factors&#148; in this prospectus and the documents incorporated by reference and our financial statements and related notes that are incorporated by reference in this
prospectus. In this prospectus, unless the context indicates otherwise, &#147;Virax,&#148; the &#147;Company,&#148; the &#147;registrant,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; or &#147;ours&#148; refer to Virax Biolabs Group Limited
and its subsidiaries. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Virax Cayman is a holding company incorporated as an exempted company under the laws of the Cayman Islands. As a holding company with no
material operations of our own, Virax Cayman conducts our operations through its operating subsidiaries in Singapore, Hong Kong, China and British Virgin Islands and has been operating since 2013. Prior to the introduction of Virax branded products
in 2020, the Group was engaged in the fast moving consumer goods (&#147;FMCG&#148;) importation business into the PRC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Virax Cayman is a
global innovative biotechnology group that primarily engages in sales, distribution and marketing of diagnostics test kits and medical technology for the prevention, detection, diagnosis and risk management of viral diseases with a particular
interest in the field of immunology. Our mission is to minimize the risks of viruses throughout the world via our products offerings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
product portfolio includes: (i)&nbsp;diagnostics test kits sold through our &#147;ViraxClear&#148; brand; (ii)&nbsp;medical technology through our &#147;ViraxCare&#148; brand; and (iii)&nbsp;sourced brands of third party suppliers, independent of
our own brands (&#147;Sourced Brands&#148;). Currently, our Group does not manufacture or develop any product that we sell in our product portfolio and we act as a distributor of third-party suppliers&#146; products. We expect to develop and launch
an upcoming brand &#147;Virax Immune&#148;, with the intention of providing an immunology profiling platform that assesses each individual&#146;s immune risk profile against major global viral diseases. We believe that the <FONT
STYLE="white-space:nowrap">T-Cell</FONT> <FONT STYLE="white-space:nowrap">in-vitro</FONT> diagnostic (&#147;IVD&#148;) Tests and immunology platform we are developing under the Virax Immune brand will be particularly useful in the diagnosis and
threat analysis of the major viruses faced globally. As of the date of the prospectus, we have developed a functioning prototype of our <FONT STYLE="white-space:nowrap">T-Cell</FONT> IVD Test under the Virax Immune brand but we are still in the
process of conducting further tests and we have not submitted any <FONT STYLE="white-space:nowrap">T-Cell</FONT> IVD Test to any regulatory agency for approval. Currently, our clinical trials and research activities for our <FONT
STYLE="white-space:nowrap">T-Cell</FONT> IVD Test under the Virax Immune brand are conducted by independent third party science companies, namely ICON Clinical Research Limited and IQ Services B.V., respectively, in the Netherlands. Prior to the
sale of our <FONT STYLE="white-space:nowrap">T-Cell</FONT> IVD Test under the Virax Immune brand in our targeted jurisdictions, namely, Canada, United Kingdom, the European Union and the United States, we must apply with the relevant authority for
the regulatory approvals. In Canada, our <FONT STYLE="white-space:nowrap">T-Cell</FONT> IVD Test will fall under Class&nbsp;I devices, which we will apply for the Health Canada Medical Device Establishment License. In the European Union, we intend
to apply our <FONT STYLE="white-space:nowrap">T-Cell</FONT> IVD Test under the self-certified Class&nbsp;A risk-based class route. Class&nbsp;A IVDs include specimen receptacles, laboratory instruments, and buffer solutions. Under the self-certified
Class&nbsp;A risk-based class route, we do not require the involvement of a notified body to obtain the CE Marking to our <FONT STYLE="white-space:nowrap">T-Cell</FONT> IVD Test. In the United Kingdom, as part of the transition due to the United
Kingdom withdrawal from the European Union, we intend to use the recognized CE marks that we will apply with the European Union for our <FONT STYLE="white-space:nowrap">T-Cell</FONT> IVD Test until June&nbsp;30, 2023 (the &#147;Transitional
Arrangement&#148;), after which, we will to conform with the UK IVD regime rather than relying on Transitional Arrangement and apply with the UK Medicine and Healthcare Products Regulatory Agency for a UK Conformity Assessed mark before we can sell
our <FONT STYLE="white-space:nowrap">T-Cell</FONT> IVD Test in the UK post June&nbsp;30, 2023. In the United States, we intend to apply our <FONT STYLE="white-space:nowrap">T-Cell</FONT> IVD Test under the Virax Immune brand under Class&nbsp;III
devices (highest risk), which are subject to most of the requirements under Class&nbsp;I and Class&nbsp;II devices as well as to <FONT STYLE="white-space:nowrap">pre-market</FONT> approval before they can be sold in the United States. For more
detailed information on the Regulatory Approval on Medical Device Products with respect to our <FONT STYLE="white-space:nowrap">T-Cell</FONT> IVD test under our Virax Immune brand, refer to &#147;<I>Regulations &#151; Summary of Regulatory Approval
on Medical Device Products (Relevant Jurisdictions)</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, our Group does not develop or manufacture any product that we
sell under the ViraxCare brand, the ViraxClear brand and Sourced Brands as we act as a distributor of third-party suppliers&#146; products. To facilitate the sales and distribution of our ViraxClear and ViraxCare products, we predominately rely on
our key third-party </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
suppliers, Nanjing Vazyme Medical Technology Co., Ltd in China for diagnostics test kits and Venus Health Consulting Limited in Hong Kong for medical technology, for product manufacturing. After
we receive our ViraxCare and ViraxClear products from our suppliers, we utilize a third party logistic company, namely, Stork Up Limited in Hong Kong, for the distribution of our products to our <FONT STYLE="white-space:nowrap">end-users</FONT> and
strategic partners overseas. However, we believe our products, in particular diagnostic test kits, provide significant value for consumers, through improved detection of diseases, improvements in health, wellness and productivity as well as by
reducing other healthcare costs, such as emergency visits and hospitalizations. Our Group also seeks to maximize consumers&#146; access to our products and services through competitive pricing and regular evaluations of our pricing arrangements and
contracts with our distributors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Previously, the <FONT STYLE="white-space:nowrap">end-users</FONT> of our distribution partners under our
ViraxClear brand include but not limited to, clinics, pharmacies, laboratories, hospitals, and other relevant groups on an international basis, covering more than 10 countries and 4 regions, including but not limited to Europe, South America, Asia
Pacific, and <FONT STYLE="white-space:nowrap">Sub-Saharan</FONT> Africa, and Our Group expects to extend our geographical reach to North America in 2022, while the <FONT STYLE="white-space:nowrap">end-users</FONT> of our dedicated online platforms
sales under our ViraxClear brand are predominately individuals and pharmacies. The <FONT STYLE="white-space:nowrap">end-users</FONT> of our ViraxCare products are predominately corporations, employees, and individual consumers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, as stated above, clinical trials and research activities for our <FONT STYLE="white-space:nowrap">T-Cell</FONT> IVD Test under the
upcoming Virax Immune brand are conducted by independent third party science companies in the Netherlands together with our Hong Kong subsidiary, Virax Immune <FONT STYLE="white-space:nowrap">T-Cell.</FONT> As our Group does not manufacture or
develop any product that we sell under the ViraxCare brand, the ViraxClear brand and Sourced Brands because we act as a distributor of third-party suppliers&#146; products, the trading and sales of these products are primarily conducted through our
SingaporeCo with some trading and sales of these products through our Logico BVI which are located in Singapore and British Virgin Islands, respectively. Shanghai Xitu is located in the PRC and is primarily engaged in procurement. Further, the
majority of our executive officers and directors are located outside of the United States and are nationals or residents of jurisdictions other than the United States, and all or a substantial portion of their assets are located outside of the
United States. Mr.&nbsp;James Foster, our Chief Executive Officer, chairman of the board of directors, holds a British Passport and currently resides in Shanghai, China; Mr.&nbsp;Jason Davis, our Chief Financial Officer, is located in the United
States and holds a United States passport; Mr.&nbsp;Mark Ternouth, our Chief Technical Officer, holds a British Passport and currently resides in Shanghai, China; Mr.&nbsp;Tomasz George, our Chief Scientific Officer, holds a British passport and
currently resides in the United Kingdom; Mr.&nbsp;Cameron Shaw, our Chief Operating Officer and director, holds a British passport and currently resides in the United Kingdom; Mr.&nbsp;Yair Erez, our independent director, holds a British passport
and currently resides in the United Kingdom; Mr.&nbsp;Evan Norton, our independent director, holds a United States passport and currently resides in the United States; and Mr.&nbsp;Nelson Haight, our independent director, holds a United States
passport and currently resides in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Initial Public Offering </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
July&nbsp;20, 2022, Virax entered into an underwriting agreement with Boustead Securities, LLC, as representatives of the several underwriters, in connection with its initial public offering (&#147;IPO&#148;) of 1,350,000 Ordinary Shares, at a price
of $5.00 per share, before deducting underwriting discounts, commissions, and other related expenses. The shares began trading on the Nasdaq Capital Market on July&nbsp;21, 2022. The Company issued Representative&#146;s Warrant to purchase up to
108,675 ordinary shares at $6.00 per share, dated July&nbsp;20, 2022, to Boustead Securities, LLC. On July&nbsp;25, 2022, the Company consummated its IPO generating gross proceeds to the Company of $7,762,500, before deducting underwriting discounts
and other related expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PIPE Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;3, 2022, Virax entered into a Securities Purchase Agreement (the &#147;PIPE Securities Purchase Agreement&#148;) with an accredited investor
(the &#147;Purchaser&#148;) for a private placement offering (&#147;Private Placement&#148;), pursuant to which the Company received gross proceeds of approximately $3,844,500, before deducting placement agent fees and other offering expenses, in
consideration of (i)1,165,000 Ordinary Shares; (b) 1,165,000 <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants <FONT STYLE="white-space:nowrap">(&#147;Pre-Funded</FONT> Warrants&#148;), and (iii) 3,495,000 warrants (&#147;Ordinary
Warrants&#148;) at a combined purchase price of $1.65 per Ordinary Share and one and a half Ordinary Warrant, or approximately $1.65 per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and one and a half Ordinary Warrant if purchasing the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants (the &#147;PIPE Offering&#148;). The Ordinary Warrants have an exercise price of
$1.73 per share, will become exercisable six months after their date of issuance and will expire five and a half years from their initial date of exercise. The PIPE Securities Purchase Agreement contains customary representations and warranties and
agreements of the Company and the Purchasers and customary indemnification rights and obligations of the parties. The PIPE Offering closed on November&nbsp;8, 2022. Concurrently with the signing of the PIPE Securities Purchase Agreement, we entered
into a Registration Rights Agreement (the &#147;Registration Rights Agreement&#148;) to file with the Securities and Exchange Commission a Registration Statement covering the resale of all of the registrable securities under the Registration Rights
Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate History and Structure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Structural Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Virax Cayman
is a holding company incorporated as an exempted company under the laws of the Cayman Islands that owns all of the outstanding capital stock of Virax Biolabs (UK) Limited and Virax Biolabs USA Management, Inc., our wholly-owned subsidiaries. Virax
Biolabs (UK) Limited, in turn, owns all of the outstanding capital stock of Virax Biolabs Limited, our wholly-owned Hong Kong subsidiary. Virax Biolabs Limited owns all of the outstanding capital stock of Virax Immune
<FONT STYLE="white-space:nowrap">T-Cell</FONT> Medical Device Company Limited, our wholly-owned Hong Kong subsidiary, and 95.65% of the outstanding capital stock of Virax Biolabs Pte. Limited, our operating subsidiary incorporated in Singapore.
Virax Biolabs Pte. Limited owns all of the outstanding capital stock of Logico Bioproducts Corp., a wholly-owned British Virgin Islands and a subsidiary of Virax Biolabs Pte. Limited. Logico Bioproducts Corp., in turn, owns all of the outstanding
capital stock of Shanghai Xitu, a wholly-owned subsidiary of Logico Bioproducts Corp. and a wholly foreign owned enterprise based in China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We completed a reorganization and share exchange of our company in September 2021 (the &#147;Reorganization&#148;). Pursuant to the
Reorganization, all shareholders of Virax Biolabs Limited (HK) transferred their shares, 102,478,548 ordinary shares in total, to Virax Biolabs (UK) Limited, in exchange for an aggregate of (i) 2,549,028 newly issued Class&nbsp;A Ordinary Shares and
(ii) 7,034,306 newly issued Class&nbsp;B Ordinary Shares of Virax Biolabs Group Limited. On June&nbsp;19, 2022, Virax Cayman underwent a shareholding restructuring whereby the Company&#146;s authorized share capital became a single class of shares
of Ordinary Shares and all of the then issued shares were <FONT STYLE="white-space:nowrap">re-designated</FONT> as Ordinary Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Organization
Structure and Purpose </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Virax Biolabs Group Limited</B> (&#147;Virax Cayman&#148;) &#151; Virax Biolabs Group Limited is a Cayman
Islands exempted company incorporated on September&nbsp;2, 2021, previously named as &#147;Virax Biolabs (Cayman) Limited&#148; and effected a name change to &#147;Virax Biolabs Group Limited&#148; on January&nbsp;19, 2022. Structured as a holding
company with no material operations, Virax Cayman conducts our operations through its operating subsidiaries in the Hong Kong, Singapore, British Virgin Islands and China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Virax Biolabs (UK) Limited </B>&#151; Virax Biolabs (UK) Limited was incorporated on August&nbsp;19, 2021 under the laws of the United
Kingdom, a wholly-owned subsidiary of Virax Cayman and structured as a holding company with no material operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Virax Biolabs USA
Management, Inc. </B>&#151; Virax Biolabs USA Management, Inc. was incorporated on August&nbsp;1, 2022 under the laws of the United States, a wholly-owned subsidiary of Virax Cayman and structured as a management company for operations within the
United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Virax Biolabs Limited </B>(&#147;HKco&#148;) &#151; Virax Biolabs Limited, incorporated on April&nbsp;14, 2020 under
the laws of Hong Kong, was previously named as &#147;Shanghai Biotechnology Devices Limited&#148; and effected a name change to &#147;Virax Biolabs Limited&#148; on July&nbsp;12, 2021. Virax Biolabs Limited, our wholly-owned Hong Kong subsidiary,
serves as a holding company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Virax Immune <FONT STYLE="white-space:nowrap">T-Cell</FONT> Medical Device Company Limited
</B>(&#147;Virax Immune <FONT STYLE="white-space:nowrap">T-Cell&#148;)</FONT> &#151; Virax Immune <FONT STYLE="white-space:nowrap">T-Cell</FONT> Medical Device Company Limited, a wholly-owned subsidiary of HKco, incorporated on January&nbsp;16, 2017
under the laws of Hong Kong, was previously named as &#147;Stork Nutrition Asia Limited&#148; and effected a name change to &#147;Virax Immune <FONT STYLE="white-space:nowrap">T-Cell</FONT> Medical Device Company Limited&#148; on September&nbsp;10,
2021. It is primarily engaged in the research and development of <FONT STYLE="white-space:nowrap">T-Cell</FONT> blood analysis. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Virax Biolabs Pte. Limited </B>(&#147;SingaporeCo&#148;) &#151; Virax Biolabs Pte.
Limited, incorporated on May&nbsp;4, 2013 under the laws of Singapore, was previously named as &#147;Natural Source Group Pte. Limited&#148; and effected a name change to &#147;Virax Biolabs Pte. Limited&#148; on July&nbsp;2, 2021. 95.65% of its
capital stock is owned by Virax Biolabs Limited and the remaining 4.35% is owned by independent third party shareholders. It is our operating company, primarily engaged in the trading and sales of our products and running primarily day to day
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Logico Bioproducts Corp. </B>(&#147;Logico BVI&#148;) &#151; Logico Bioproducts Corp., a wholly-owned subsidiary of
SingaporeCo, is a limited liability company incorporated in the British Virgin Islands on January&nbsp;21, 2011, and is primarily engaged in the trading and sales of our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Shanghai Xitu Consulting Co., Limited</B> (&#147;Shanghai Xitu&#148;) &#151; Shanghai Xitu, a wholly-owned subsidiary of Logico BVI and a
wholly foreign owned enterprise, is a limited liability company incorporated on October&nbsp;27, 2017 in China. Shanghai Xitu is primarily engaged in procurement. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following diagram illustrates our corporate structure immediately following the
consummation of this offering: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g423556g13s02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulations and Approvals for the PIPE Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As some of our operations are currently conducted through our operating entities established in Hong Kong and Shanghai, namely, HKco, Virax
Immune <FONT STYLE="white-space:nowrap">T-Cell,</FONT> Shanghai Xitu, we are potentially subject to significant regulations by various agencies of the Chinese government. The Regulations on Mergers and Acquisitions of Domestic Companies by Foreign
Investors, or the M&amp;A Rules, adopted by six PRC regulatory agencies in 2006 and amended in 2009, require an overseas special purpose vehicle formed for listing purposes through acquisitions of PRC domestic companies and controlled by PRC
companies or individuals to obtain the approval of the CSRC and Ministry of Commerce of the PRC (&#147;MOFCOM&#148;), prior to the listing and trading of such special purpose vehicle&#146;s securities on
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an overseas stock exchange. Substantial uncertainty remains regarding the scope and applicability of the M&amp;A Rules to offshore special purpose vehicles. As of the closing date of the PIPE
Offering, that CSRC&#146;s approval under the M&amp;A Rules is not required for the listing and trading of our Ordinary Shares on Nasdaq in the context of this offering given that we are an exempted company with limited liability incorporated under
the laws of the Cayman Islands with some operations located in Hong Kong and the PRC controlled by <FONT STYLE="white-space:nowrap">non-PRC</FONT> citizens. As such, we do not fit into the definition of &#147;overseas special purpose vehicle&#148;
under the M&amp;A Regulations and we have never conducted any merger or acquisitions of any PRC domestic companies with a related party relationship. MOFCOM&#146;s approval under the M&amp;A Rules is also not required as we have never conducted any
merger or acquisitions of any PRC domestic companies with a related party relationship. We cannot assure you that relevant PRC governmental agencies, including the CSRC, would reach the same conclusion as we do. If we or our subsidiaries
inadvertently conclude that such approval is not required, our ability to offer or continue to offer our Ordinary Shares to investors could be significantly limited or completed hindered, which could cause the value of our Ordinary Shares to
significantly decline or become worthless. Our Group or Shanghai Xitu may also face sanctions by the CSRC, the CAC or other PRC regulatory agencies. These regulatory agencies may impose fines and penalties on our operations in China, limit our
ability to pay dividends outside of China, limit our operations in China, delay or restrict the repatriation of the proceeds from this offering into China or take other actions that could have a material adverse effect on our business, financial
condition, results of operations and prospects, as well as the trading price of our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2021, the General Office
of the Central Committee of the Communist Party of China and the General Office of the State Council jointly issued the Opinions on Strictly Cracking Down on Illegal Securities Activities According to Law (the &#147;Opinions&#148;), which called for
strengthened regulation over illegal securities activities and supervision on overseas listings by China-based companies and propose to take effective measures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the closing date of the PIPE Offering, no official guidance or related implementation rules have been issued in relation to the
Opinions, and the interpretation and implementation of the Opinions also remain unclear to some extent at this stage. Based on our understanding of the current PRC laws and regulations in effect at the time of this prospectus, no prior permission is
required under the M&amp;A Rules or the Opinions from any PRC governmental authorities (including the CSRC) for consummating this offering by our company. However, there can be no assurance that the relevant PRC governmental authorities, including
the CSRC, would reach the same conclusion as us, or that the CSRC or any other PRC governmental authorities would not promulgate new rules or new interpretation of current rules (with retrospective effect) to require us to obtain CSRC or other PRC
governmental approvals for this offering. If we or our subsidiaries inadvertently conclude that such permission is not required, our ability to offer or continue to offer our Ordinary Shares to investors could be significantly limited or completed
hindered, which could cause the value of our Ordinary Shares to significantly decline or become worthless. Our Group or Shanghai Xitu may also face sanctions by the CSRC, the CAC or other PRC regulatory agencies. These regulatory agencies may impose
fines and penalties on our operations in China, limit our ability to pay dividends outside of China, limit our operations in China, delay or restrict the repatriation of the proceeds from this offering into China or take other actions that could
have a material adverse effect on our business, financial condition, results of operations and prospects, as well as the trading price of our securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;28, 2021, the Cyberspace Administration of China (the &#147;CAC&#148;), published the Measures for Cybersecurity Review which
became effective on February&nbsp;15, 2022, which required that any &#147;network platform operator&#148; controlling personal information of no less than one million users which seeks to list on a foreign stock exchange should also be subject to
cybersecurity review. The PRC Data Security Law, which took effect on September&nbsp;1, 2021, imposes data security and privacy obligations on entities and individuals that carry out data activities, provides for a national security review procedure
for data activities that may affect national security and imposes export restrictions on certain data and information. On August&nbsp;20, 2021, the Standing Committee of the People&#146;s Congress promulgated the PRC Personal Information Protection
Law (the &#147;PIPL&#148;), which took effect on November&nbsp;1, 2021. The PIPL sets out the regulatory framework for handling and protection of personal information and transmission of personal information to overseas. Shanghai Xitu is not a
network platform operator, nor do we conduct data activities that may affect national security or hold personal information of more than one million users. In addition, we do not conduct any cross border transfer of personal information from the PRC
to other jurisdictions. As such, we do not believe the Virax Group falls in the &#147;operators of critical information infrastructure&#148; as mentioned above and we are not subject to PRC cybersecurity review. However, the Measures for
Cybersecurity Review (2021 version), the Data Security Law and the PIPL were recently adopted and remain unclear on how they will be interpreted, amended and implemented by the relevant PRC governmental authorities. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;24, 2021, the State Council published the draft Administrative Provisions
on the Overseas Issuance and Listing of Securities by Domestic Companies (Draft for Comments) (the &#147;Administrative Provisions&#148;), and the CSRC published the draft Measures for Record-filings of the Overseas Issuance and Listing of
Securities by Domestic Companies (Draft for Comments) (the &#147;Administrative Measures&#148;), for public comment. It should be noted that neither the Administrative Provisions nor the Administrative Measures have come into effect as of the date
of this registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Article 2 of the Administrative Measures, domestic enterprises that directly or
indirectly offer or list securities on an overseas stock exchange shall file with the CSRC. We are not &#147;directly&#148; offering securities overseas (as Shanghai Xitu is not the issuer of the listed securities on an overseas stock exchange).
According to the Administrative Measures, if the issuer meets the following conditions, it shall be deemed as an &#147;indirect&#148; overseas offering and listing of a domestic enterprise: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the operating income, total profit, total assets or net assets of the domestic enterprise in the most recent
fiscal year account for more than 50% of the relevant data in the issuer&#146;s audited consolidated financial statements for the same period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">most of the senior management personnel responsible for business operation and management are Chinese Citizens
or having a ordinary residence located in the PRC, and the principal place of business operation is located in or mainly within the PRC. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the above mentioned Administrative Provisions and Administrative Measures (both are in draft form only), given that the operating
income, total profit, total assets or net assets of the Shanghai Xitu for the last financial year accounted for less than 50% of the Virax Group&#146;s audited consolidated financial statements and none of Shanghai Xitu&#146;s senior management
personnel is a PRC Citizen and only two (2)&nbsp;out of seven (7)&nbsp;have an ordinary residence located in the PRC, this offering shall not be deemed as a domestic enterprise that indirectly offer or list securities on an overseas stock exchange,
nor does it requires filing or approvals from the CSRC. However, there can be no assurance that the relevant PRC governmental authorities, including the CSRC, would reach the same conclusion as us, or that the CSRC or any other PRC governmental
authorities would not promulgate new rules or new interpretation of current rules (with retrospective effect) to require us to obtain CSRC or other PRC governmental approvals for this offering. If we or our subsidiaries inadvertently conclude that
such approvals are not required, our ability to offer or continue to offer our Ordinary Shares to investors could be significantly limited or completed hindered, which could cause the value of our Ordinary Shares to significantly decline or become
worthless. Our Group or Shanghai Xitu may also face sanctions by the CSRC, the CAC or other PRC regulatory agencies. These regulatory agencies may impose fines and penalties on our operations in China, limit our ability to pay dividends outside of
China, limit our operations in China, delay or restrict the repatriation of the proceeds from this offering into China or take other actions that could have a material adverse effect on our business, financial condition, results of operations and
prospects, as well as the trading price of our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have been closely monitoring regulatory developments in China regarding any
necessary approvals from the CSRC or other PRC governmental authorities required for overseas listings, including this offering. Our business may be subject to various government regulations and regulatory interference. As of the date of this
prospectus, (i)&nbsp;Shanghai Xitu has obtained all necessary permissions or approvals and authorizations in the PRC in all material aspects in relation to conducting its business operations in China; and (ii)&nbsp;we are not required to obtain any
permission or approval from any PRC authority to issue securities to foreign investors (by Virax Cayman) or in connection with this offering under PRC laws or regulations in effect. Except for the business license issued by the local branch of the
State Administration for Market Regulation, which Shanghai Xitu&#146;s have obtained and are in full force and effect as of the date of this prospectus, Shanghai Xitu is not required to obtain any other licenses, approvals or permits to conduct its
business operations in China. To the best of our knowledge, as of the date of this prospectus, there are no laws or regulations that are or will be adopted in the near future by PRC government authorities that would prevent Shanghai Xitu from
maintaining the business license it has obtained or would require it to obtain additional licenses or qualifications in order to operate its current business operations. Further, there are no PRC laws and regulations (including the CSRC, the CAC, or
any other government entity) in force explicitly requiring that our Group or Shanghai Xitu to obtain permission from PRC authorities for this offering or to issue securities to foreign investors (by Virax Cayman) and we are not required to obtain
additional permission or approval from Chinese authorities, including the CSRC and the CAC, to either approve our PRC subsidiaries&#146; operation or to offer the securities (of Virax Cayman) being registered to foreign investors. Nevertheless, we
may incur increased costs necessary to comply with </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
existing and newly adopted laws and regulations or penalties for any failure to comply. Furthermore, given recent statements by the Chinese government indicating an intent to exert more oversight
and control over offerings that are conducted overseas, although as of the date of this prospectus, our Group or Shanghai Xitu have not been involved in any investigations initiated by the applicable governmental regulatory authorities, nor have we
received any inquiry, notice, warning, or sanction in such respect, there remains uncertainty as to the enactment, interpretation and implementation of regulatory requirements related to overseas securities offerings and other capital markets
activities. If it is determined in the future that the approval of the CSRC, the CAC or any other regulatory authority is required for this offering, our Group or Shanghai Xitu may face sanctions by the CSRC, the CAC or other PRC regulatory
agencies. These regulatory agencies may impose fines and penalties on our operations in China, limit our ability to pay dividends outside of China, limit our operations in China, delay or restrict the repatriation of the proceeds from the PIPE
Offering into China or take other actions that could have a material adverse effect on our business, financial condition, results of operations and prospects, as well as the trading price of our securities. Consequently, if you engage in market
trading or other activities in anticipation of and prior to settlement and delivery of the Ordinary Shares that we are offering, you do so at the risk that settlement and delivery may not occur. In addition, if the CSRC, the CAC or other regulatory
PRC agencies later promulgate new rules requiring that our Group or Shanghai Xitu obtain their approvals for this PIPE Offering, our Group or Shanghai Xitu may be unable to obtain a waiver of such approval requirements, if and when procedures are
established to obtain such a waiver. Any uncertainties and/or negative publicity regarding such an approval requirement could have a material adverse effect on our ability to complete this offering or any
<FONT STYLE="white-space:nowrap">follow-on</FONT> offering of our securities or the market for and market price of our ordinary shares, significantly limit or completely hinder our ability to offer or continue to offer securities to investors, or
cause such securities to significantly decline in value or become worthless. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer of Cash Through our Organization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, Virax Cayman is incorporated in Cayman Islands to be the ultimate parent company of the Group. As a holding company with no material
operations of our own, Virax Cayman conduct our operations through our operating subsidiaries established in Singapore, Hong Kong, China, and the British Virgin Islands. Currently, Virax Cayman indirectly owns 95.65% of the equity interests in
SingaporeCo. However, some of our operations are currently conducted through our operating entities established in Hong Kong and Shanghai, primarily, Virax Immune <FONT STYLE="white-space:nowrap">T-Cell</FONT> Medical Device Company Limited and
Shanghai Xitu Consulting Co., Limited, which we refer to as Virax Immune <FONT STYLE="white-space:nowrap">T-Cell</FONT> and Shanghai Xitu, respectively. Virax Cayman is permitted under the laws of Cayman Islands to provide funding to our
subsidiaries in Singapore, British Virgin Islands, Hong Kong and Shanghai through loans or capital contributions on the amount of the funds. Virax Cayman can distribute earnings from its businesses, including subsidiaries, to the U.S. investors as
well as the ability to settle amounts owed under intercompany agreements. Our operations in Singapore, British Virgin Islands, Hong Kong and Shanghai were in loss position since 2020, and the Group has raised capital through financing transactions
and provided funding to our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operating subsidiaries are permitted under the laws of Singapore, British Virgin Islands, PRC
and Hong Kong, respectively, to provide funding to Virax Cayman, the holding company incorporated in the Cayman Islands through dividend distributions. Our Group currently intend to retain all available funds and future earnings, if any, for the
operation and expansion of our business and do not anticipate declaring or paying any dividends in the foreseeable future. We currently do not have any dividend policy, and we do not anticipate declaring or paying dividends in the foreseeable
future. We intend to retain all available funds and any future earnings to fund the development and expansion of our business. If our subsidiaries incurs debt on its own behalf in the future, the instruments governing such debt may restrict their
ability to pay dividends to us. As of the date of this prospectus, there have been cash flows between our subsidiaries, and cash flows between our Virax Cayman and our subsidiaries to fund operations in the normal course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, some of our operations are currently conducted through our operating entities established in Hong Kong and Shanghai. We did not
have or intend to set up any subsidiary or enter into any contractual arrangements to establish a VIE structure with any entity in China. Since Hong Kong is a special administrative region of the PRC and the basic policies of the PRC regarding Hong
Kong are reflected in the Basic Law, providing Hong Kong with a high degree of autonomy and executive, legislative and independent judicial powers, including that of final adjudication under the principle of &#147;one country, two systems&#148;.
Under Hong Kong law, dividends could only be paid out of distributable profits (that is, accumulated realized profits less accumulated realized losses) or other distributable reserves. Dividends cannot be paid out of share capital. Under the current
practice of the Inland Revenue Department of Hong Kong, no tax is payable in Hong Kong in respect of dividends paid by us. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the PRC government imposes controls on the convertibility of RMB into foreign
currencies and, in certain cases, the remittance of currency out of China. The dividends and distributions from Shanghai Xitu is subject to relevant regulations and restrictions on dividends and payment to parties outside of China. Investment in
Chinese companies, which are governed by the Foreign Investment Law and Company Law, and the dividends and distributions from Shanghai Xitu is subject to relevant regulations and restrictions on dividends and payment to parties outside of China.
Applicable PRC law permits payment of dividends to Virax Cayman by Shanghai Xitu only out of its net income, if any, determined in accordance with PRC accounting standards and regulations. Shanghai Xitu is required to set aside a portion of its net
income, if any, each year to fund general reserves for appropriations until such reserves have reached 50% of the relevant entity&#146;s registered capital. These reserves are not distributable as cash dividends. A PRC company is not permitted to
distribute any profits until any losses from prior fiscal years have been offset. Profits retained from prior fiscal years may be distributed together with distributable profits from the current fiscal year. In addition, registered share capital and
capital reserve accounts are also restricted from withdrawal in the PRC, up to the amount of net assets held in each operating subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within the organization, investor cash inflows have all been received by Virax Cayman. Cash to fund Virax Cayman&#146;s operations is
transferred from Virax Cayman down through our Singapore, Hong Kong, BVI entities and then into our Chinese entity through capital contributions and loans. Transfers among our Singapore and Hong Kong entities are not restricted. Furthermore, subject
to payment of withholding taxes, there are no restrictions and limitations on our ability to distribute earnings from our subsidiaries to Virax Cayman and U.S. investors as well as the ability to settle amounts owed under any agreements. No
dividends or distribution have been made by our subsidiaries or by Virax Cayman to date and we intend to reinvest all cash into our subsidiaries for the foreseeable future. For the years ended March&nbsp;31, 2021 and 2020 and for the six months
ended September&nbsp;30, 2021, there was no transfer of funds between Virax Cayman and its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, subject to the
Companies Act and our Second Amended and Restated Memorandum and Articles of Association, our board of directors may authorize and declare a dividend to shareholders from time to time out of the profits from Virax Cayman, realized or unrealized, or
out of the share premium account, provided that Virax Cayman will remain solvent, meaning Virax Cayman is able to pay its debts as they come due in the ordinary course of business. There is no further Cayman Islands statutory restriction on the
amount of funds which may be distributed by us in the form of dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no restrictions or limitations under the laws of
Singapore imposed on the conversion of Singapore dollars into foreign currencies and the remittance of currencies out of Singapore, nor is there any restriction on any foreign exchange to transfer cash between Virax Cayman and its subsidiaries,
across borders and to foreign investors outside of Singapore, nor is there any restrictions and limitations to distribute earnings from the subsidiaries, to Virax Cayman and investors outside of Singapore and amounts owed as well as the ability to
settle amounts owed under intercompany agreements. There are no foreign exchange controls in Singapore. For the years ended March&nbsp;31, 2021 and 2020, there was no transfer between Virax Cayman and its subsidiaries. As of the date of this
prospectus and for the year ended March&nbsp;31, 2021 and 2020, we have not declared any dividend. If we determine to pay dividends on any of our Ordinary Shares in the future, as a holding company, we will be dependent on receipt of funds from our
operating subsidiaries in Singapore, British Virgin Islands and Hong Kong. Under the current practice of the Inland Revenue Authority of Singapore, no tax is payable in Singapore, in respect of dividends paid by us, and under the current laws of the
Cayman Islands, we are also not subject to tax on income or capital gains and withholding tax is not imposed upon payments of dividends from Virax Cayman to its shareholders. Under the current practice of the Inland Revenue Department of Hong Kong,
no tax is payable in Hong Kong in respect of dividends paid by us. Further, we do not have specific cash management policies and procedures in place that dictate how funds are transferred through our organization, however, we have been closely
monitoring our transfer of funds and will adopt relevant policies and procedures if necessary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and a
Foreign Private Issuer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Emerging Growth Company </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a company with less than $1.07&nbsp;billion in revenue during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as
defined in the Jumpstart Our Business Startups Act, or JOBS Act, enacted in April 2012, and may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not limited to:
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to present only two years of audited financial statements and only two years of related
Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations in our filings with the SEC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control
over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation in periodic reports, proxy statements and
registration statements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder
approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions until the
last day of our fiscal year following the fifth anniversary of the date of the first sale of our Ordinary Shares pursuant to this offering. However, if certain events occur before the end of such five-year period, including if we become a
&#147;large accelerated filer,&#148; our annual gross revenues exceed $1.07&nbsp;billion or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an
emerging growth company before the end of such five-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Section&nbsp;107 of the JOBS Act provides that an
&#147;emerging growth company&#148; can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. We
have elected to take advantage of the extended transition period for complying with new or revised accounting standards and acknowledge such election is irrevocable pursuant to Section&nbsp;107 of the JOBS Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign Private Issuer </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
&#147;foreign private issuer,&#148; as defined by the SEC. As a result, in accordance with the rules and regulations of The Nasdaq Stock Market LLC, or Nasdaq, we may comply with home country governance requirements and certain exemptions thereunder
rather than complying with Nasdaq corporate governance standards. We may choose to take advantage of the following exemptions afforded to foreign private issuers: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exemption from filing quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or provide current
reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> disclosing significant events within four (4)&nbsp;days of their occurrence. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exemption from Section&nbsp;16 rules regarding sales of Ordinary Shares by insiders, which will provide less data
in this regard than shareholders of U.S. companies that are subject to the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exemption from the Nasdaq rules applicable to domestic issuers requiring disclosure within four (4)&nbsp;business
days of any determination to grant a waiver of the code of business conduct and ethics to directors and officers. Although we will require board approval of any such waiver, we may choose not to disclose the waiver in the manner set forth in the
Nasdaq rules, as permitted by the foreign private issuer exemption. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exemption from the requirement that our board of directors have a compensation committee that is composed
entirely of independent directors with a written charter addressing the committee&#146;s purpose and responsibilities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exemption from the requirements that director nominees are selected, or recommended for selection by our board of
directors, either by (i)&nbsp;independent directors constituting a majority of our board of directors&#146; independent directors in a vote in which only independent directors participate, or (ii)&nbsp;a committee comprised solely of independent
directors, and that a formal written charter or board resolution, as applicable, addressing the nominations process is adopted. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, Nasdaq Rule 5615(a)(3) provides that a foreign private issuer, such as us, may rely on our home country corporate governance
practices in lieu of certain of the rules in the Nasdaq Rule 5600 Series and Rule 5250(d), provided that we nevertheless comply with Nasdaq&#146;s Notification of Noncompliance requirement (Rule 5625), the Voting Rights requirement (Rule 5640) and
that we have an audit committee that satisfies Rule 5605(c)(3), consisting of committee members that meet the independence requirements of Rule 5605(c)(2)(A)(ii). If we rely on our home </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
country corporate governance practices in lieu of certain of the rules of Nasdaq, our shareholders may not have the same protections afforded to shareholders of companies that are subject to all
of the corporate governance requirements of Nasdaq. If we choose to do so, we may utilize these exemptions for as long as we continue to qualify as a foreign private issuer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we are permitted to follow certain corporate governance rules that conform to Cayman Islands requirements in lieu of many of the
Nasdaq corporate governance rules, we intend to comply with the Nasdaq corporate governance rules applicable to foreign private issuers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate
Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive office is located at 30 Broadwick Street London, W1F 8LX, United Kingdom. Our telephone number is
+44 020 7788 7414. Our registered office in the Cayman Islands is located at the office of Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-9009,</FONT> Cayman Islands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42<SUP
STYLE="font-size:75%; vertical-align:top">nd</SUP> Street, 18<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, New York, NY 10168. Our principal website is located at <I>https://viraxbiolabs.com/</I>. Information contained on, or that
can be accessed through, our website is not a part of, and shall not be incorporated by reference into, this prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom423556_3"></A>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Ordinary Shares to be Offered by the Selling Shareholders </P></TD>
<TD>Up to 5,825,000<B> </B>of our Ordinary Shares. These 5,825,000<B> </B>Ordinary Shares consist of (i) 1,165,000 Ordinary Shares (the &#147;PIPE Shares&#148;) issued pursuant to the securities purchase agreement, dated as of November&nbsp;3, 2022,
by and between Armistice Capital Master Fund Ltd. (the &#147;PIPE Securities Purchase Agreement&#148;); (ii) 1,165,000 Ordinary Shares (the <FONT STYLE="white-space:nowrap">&#147;Pre-Funded</FONT> Warrant Shares&#148;) issued or issuable upon the
exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (the <FONT STYLE="white-space:nowrap">&#147;Pre-Funded</FONT> Warrants&#148;) that were issued pursuant to the PIPE Securities Purchase Agreement; (iii) 3,495,000 Ordinary
Shares (the &#147;Warrant Shares&#148;) issued or issuable upon the exercise of ordinary warrants (the &#147;Ordinary Warrants&#148;) that were issued pursuant to the PIPE Securities Purchase Agreement. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </P></TD>
<TD>All Ordinary Shares offered by this prospectus are being registered for the accounts of the selling shareholders and we will not receive any proceeds from the sale of these shares. However, we have received and will receive proceeds from the
exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the Ordinary Warrants if they are exercised for cash. We intend to use those proceeds, if any, for general working corporate purposes. See &#147;<I>Use of
Proceeds</I>&#148; beginning on page 19 of this prospectus for additional information. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Registration Rights </P></TD>
<TD>Under the terms of the Registration Rights Agreement, we agreed to file this registration statement with respect to the registration of the resale by the selling shareholders of the PIPE Shares, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrant Shares, and the Warrant Shares (collectively, the &#147;Resale Shares&#148;), as applicable, by the 15<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> calendar day following the date of the Registration Rights Agreement, and to use
best efforts to have the registration statement declared effective as promptly as practical, and in any event, no later than the 30<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> calendar day following the date of the Registration Rights
Agreement or in the event of a full review by the SEC, the 45<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> calendar day following the date of the Registration Rights Agreement in the event that the Initial Registration Statement is not
declared effective by the Commission prior to December&nbsp;31, 2022. In addition, we agreed that, upon the registration statement being declared effective under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), we will use
our reasonable best efforts to keep such registration statement continuously effective under the Securities Act until the date that all securities registerable pursuant to such registration statement (i)&nbsp;have been sold, thereunder or pursuant
to Rule 144, or (ii)&nbsp;may be sold without volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions pursuant to Rule 144 and without the requirement for us to be in compliance with the
current public information requirement under Rule 144. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;<I>Selling Shareholders</I>&#148; on page 20 of this prospectus for additional information. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Plan of Distribution </P></TD>
<TD>The selling shareholders named in this prospectus, or their pledgees, donees, transferees, distributees, beneficiaries or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest,</FONT></FONT> may offer or
sell the ordinary shares from time to time through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. The selling shareholders may also resell the ordinary
shares to or through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or commissions. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;<I>Plan of Distribution</I>&#148; beginning on page 21 of this prospectus for additional information on the methods of sale that may be used by the selling shareholders. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Market Symbol </P></TD>
<TD>Our ordinary shares are listed on The Nasdaq Capital Market under the symbol &#147;VRAX.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </P></TD>
<TD>Investing in our ordinary shares involves significant risks. See &#147;<I>Risk Factors</I>&#148; beginning on page 15 of this prospectus and the documents incorporated by reference in this prospectus. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom423556_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves a high degree of risk. In addition to the other information contained in this prospectus and in the documents we
incorporate by reference herein, you should carefully consider the risks discussed below and under the heading &#147;Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the fiscal year ended
March&nbsp;31, 2022 as well as any amendment or update to our risk factors reflected in subsequent filings with the SEC, before making a decision about investing in our securities. The risks and uncertainties discussed below and in the documents
incorporated by reference are not the only ones facing us. Additional risks and uncertainties not presently known to us, or that we currently see as immaterial, may also harm our business. If any of these risks occur, our business, financial
condition and operating results could be harmed, the trading price of our ordinary shares could decline and you could lose part or all of your investment. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering and our Ordinary shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience future dilution as a result of future equity offerings and other issuances of our securities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to raise additional capital, we may in the future offer additional ordinary shares or other securities convertible into or exchangeable for our
ordinary shares at prices that may not be the same as the price per share paid by the investors in this offering. We may not be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the
price per share paid by the investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing shareholders. The price per share at which we sell additional ordinary shares or
securities convertible into ordinary shares in future transactions may be higher or lower than the price per share paid to the selling shareholders. Our shareholders will incur dilution upon exercise of any outstanding stock options, warrants or
other convertible securities or upon the issuance of ordinary shares under our share incentive programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to require additional capital in the
future in order to develop our product candidates, which are in early stages of development. If we do not obtain any such additional financing, it may be difficult to effectively realize our long-term strategic goals and objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current cash resources will not be sufficient to fund the development of our product candidates through all of the required clinical trials to receive
regulatory approval and commercialization. If we cannot secure this additional funding when such funds are required, we may fail to develop our product candidates or be forced to forego certain strategic opportunities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any additional capital raised through the sale of equity or equity-backed securities may dilute our shareholders&#146; ownership percentages and could also
result in a decrease in the market value of our equity securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of any securities issued by us in future capital transactions may be more
favorable to new investors, and may include preferences, superior voting rights and the issuance of warrants or other derivative securities, which may have a further dilutive effect on the holders of any of our securities then outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities
law compliance fees, printing and distribution expenses and other costs. We may also be required to recognize <FONT STYLE="white-space:nowrap">non-cash</FONT> expenses in connection with certain securities we issue, such as convertible notes and
warrants, which may adversely impact our financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of our ordinary shares could reduce the market price of our ordinary
shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or our existing shareholders, our directors or their affiliates or certain of our executive officers, sell a substantial number of
our ordinary shares in the public market, including the Resale Shares once issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant and Ordinary Warrants, the market price of our ordinary shares could decrease
significantly. The perception in the public market that we or our shareholders might sell our Ordinary Shares could also depress the market price of our ordinary shares and could impair our future ability to obtain capital, especially through an
offering of equity securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have made significant offerings of our ordinary shares in the past and may do so again in the future.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of our ordinary shares may be subject to fluctuation and you could lose all or part of your investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ordinary shares were first offered publicly in our IPO in July 2020 at a price of $5.00 per share, and our ordinary shares have subsequently traded as high
as $20.86 per share and as low as $1.32 per share through November&nbsp;17, 2022. The market price of our ordinary shares on the Nasdaq Capital Market may fluctuate as a result of a number of factors, some of which are beyond our control, including,
but not limited to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the volume and timing of sales of our products; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the introduction of new products or product enhancements by us or others in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes or other developments with respect to our or others&#146; intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop, obtain regulatory clearance or approval for, and market new and enhanced products on a
timely basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product liability claims or other litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">quarterly variations in our results of operations or those of others in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">media exposure of our products or of those of others in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in governmental regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in earnings estimates or recommendations by securities analysts; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general market conditions and other factors, including factors unrelated to our operating performance or the
operating performance of our competitors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These factors and any corresponding price fluctuations may materially and adversely affect
the market price of our ordinary shares and result in substantial losses being incurred by our investors. In the past, following periods of market volatility, public company shareholders have often instituted securities class action litigation. If
we were involved in securities litigation, it could impose a substantial cost upon us and divert the resources and attention of our management from our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom423556_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify
forward-looking statements by the words &#147;may,&#148; &#147;might,&#148; &#147;will,&#148; &#147;could,&#148; &#147;would,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;goal,&#148;
&#147;objective,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;continue&#148; and &#147;ongoing,&#148; or the negative of these terms, or other comparable terminology
intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially
different from the information expressed or implied by these forward-looking statements. The forward-looking statements and opinions contained in this prospectus are based upon information available to us as of the date of this prospectus and, while
we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all
potentially available relevant information. Forward-looking statements include statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timing of the development of future business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">capabilities of our business operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expected future economic performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition in our market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continued market acceptance of our services and products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">protection of our intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the laws that affect our operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inflation and fluctuations in foreign currency exchange rates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain all necessary government certifications, approvals, and/or licenses to conduct
our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continued development of a public trading market for our securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of complying with current and future governmental regulations and the impact of any changes in the
regulations on our operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing our growth effectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">projections of revenue, earnings, capital structure and other financial items; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fluctuations in operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dependence on our senior management and key employees; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other factors set forth under &#147;Risk Factors.&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should refer to the section titled &#147;Risk Factors&#148; for a discussion of important factors that may cause our actual results to
differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate. Furthermore, if our
forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any
other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise,
except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we reference in this prospectus and have filed as
exhibits to the registration statement, of which this prospectus forms a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by
these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom423556_6"></A>MARKET, INDUSTRY AND OTHER DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, including the information incorporated by reference into this prospectus and any free writing prospectus that we have
authorized for use in connection with this offering, contain estimates, projections and other information concerning our industry, our business and the markets for our product candidates, including data regarding total sales of products, the
addressable market and patient population, their projected growth rates, the perceptions and preferences of patients and physicians regarding the disease indications that we are pursuing or may pursue, as well as data regarding market research,
estimates and forecasts prepared by our senior management. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ
materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market
research firms and other third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or
more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. In addition,
assumptions and estimates of our and our industry&#146;s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause our future performance to differ materially
from our assumptions and estimates. See also &#147;<I>Special Note Regarding Forward-Looking Statements</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom423556_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All ordinary shares offered by this prospectus are being registered for the accounts of the selling shareholders and we will not receive any
proceeds from the sale of these shares. However, we have received and we may receive proceeds from the exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and Ordinary Warrants, if and when exercised, to the extent that they
are exercised for cash. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and Ordinary Warrants, however, are also exercisable on a cashless basis under certain circumstances. For the purposes of this registration statement, we have
assumed the full exercise for cash of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and Ordinary Warrants, in which case the gross proceeds of such exercise will be approximately $6,046,350. We intend to use those proceeds, if any,
for funding of our research and development activities for our Virax Immune platform and for general corporate purposes. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom423556_8">
</A>DESCRIPTION OF SHARE CAPITAL AND GOVERNING DOCUMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A description of our share capital and our ordinary shares can be found in
Exhibit 1.1 to our Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> filed with the SEC on August&nbsp;12, 2022 and is incorporated by reference herein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized share capital
consists of 50,000,000 ordinary shares, par value $0.0001 per share, of which 12,827,789 shares are issued and outstanding as of November&nbsp;18, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our outstanding ordinary shares are validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> Our ordinary
shares are not redeemable and do not provide any preemptive rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Ordinary Shares are listing on the Nasdaq Capital Market under the symbol &#147;VRAX&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar of Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our Ordinary Shares is Continental Stock Transfer&nbsp;&amp; Trust Company. The transfer agent and
registrar&#146;s address is 1 State Street, 30<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, New York, NY 10004. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom423556_9"></A>SELLING SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, as used in this prospectus, &#147;selling shareholders&#148; includes the selling shareholders listed below and donees,
pledgees, transferees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling shares received after the date of this prospectus from the selling shareholders as a gift, pledge or other <FONT
STYLE="white-space:nowrap">non-sale</FONT> related transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have prepared this prospectus to allow the selling shareholders or their successors,
assignees or other permitted transferees to sell or otherwise dispose of, from time to time, up to 5,825,000 ordinary shares, which are comprised of (i) 1,165,000 Ordinary Shares, (ii) 1,165,000 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrant Shares, and (ii) 3,495,000 Ordinary Warrant Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below lists the selling shareholder and other information regarding the beneficial
ownership of the Ordinary Shares by the selling shareholder. The second column lists the number of Ordinary Shares beneficially owned by the selling shareholder, based on its ownership of the Ordinary Shares, as of November&nbsp;17, 2022. The third
column lists the Ordinary Shares being offered by this prospectus by the selling shareholder. The fourth column assumes the sale of all of the shares offered by the selling shareholder pursuant to this prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus covers the resale of the sum of (i)&nbsp;the maximum number of PIPE Shares, (ii)&nbsp;the maximum number of
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares, and (iii)&nbsp;the maximum number of Warrant Shares. The table below assumes that the outstanding warrants were exercised in full as of the trading day immediately preceding the date
this registration statement was initially filed with the SEC, each as of the trading day immediately preceding the applicable date of determination and all subject to adjustment as provided in the PIPE Securities Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the Ordinary Warrants, a selling shareholder, who elected to be subject
to such limitation (as indicated in the table below), may not exercise such warrants to the extent such exercise would cause such selling shareholder, together with its affiliates and attribution parties, to beneficially own a number of ordinary
shares which would exceed 4.99% (or 9.99% at the election of the holder prior to the date of issuance), of our then outstanding ordinary shares following such exercise, excluding for purposes of such determination ordinary shares issuable upon the
exercise of such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and Ordinary Warrants which have not been exercised. The number of shares in the second and fourth columns do not reflect this limitation. The selling shareholders may sell
all, some or none of their shares in this offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Name of Selling</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Shareholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>ordinary</B><br><B>shares&nbsp;owned</B><br><B>prior to</B><br><B>offering (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum&nbsp;number&nbsp;of&nbsp;ordinary</B><br><B>shares to be</B><br><B>sold</B><br><B>pursuant to</B><br><B>this</B><br><B>Prospectus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;ordinary</B><br><B>shares owned after</B><br><B>offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Armistice Capital, LLC (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,825,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,825,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The securities are directly held by Armistice Capital Master Fund Ltd. (the &#147;Master Fund&#148;), a Cayman
Islands exempted company, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC (&#147;Armistice&#148;), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital.
Armistice and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein. The Pre-Funded Warrant Shares are subject to a 9.99% beneficial ownership limitation and the
Ordinary Warrants are subject to a 4.99% beneficial ownership limitation, which prohibit the Master Fund from exercising any portion of either of them if, following such exercise, the Master Fund&#146;s ownership of our ordinary shares would exceed
the applicable limitation. The amounts and percentages in the table do not reflect the application of those limitations. The address of the Master Fund is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, NY 10022.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,165,000 PIPE Shares. In addition, the selling stockholder holds
<FONT STYLE="white-space:nowrap">(i)&nbsp;Pre-Funded</FONT> Warrants to acquire 1,165,000 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares, and (ii)&nbsp;Ordinary Warrants to acquire 3,495,000 Ordinary Warrant Shares.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Relationships and Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;3, 2022, we entered into the PIPE Securities Purchase Agreement, with the selling stockholder, pursuant to which we issued and
sold to the selling shareholder 1,165,000 newly issued shares of our Ordinary Shares, 1,165,000 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to purchase Ordinary Shares at an exercise price per share of $0.0001, and 3,495,000 Ordinary
Warrants to purchase shares of Common Stock at an exercise price per share of $1.73, for gross proceeds of approximately $3.8&nbsp;million. The Private Placement closed on November&nbsp;8, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the PIPE Securities Purchase Agreement and the Registration Rights Agreement, we agreed to
prepare and file with the SEC within 15 days of the execution of the PIPE Securities Purchase Agreement a registration statement covering the resale of the shares of our Common Stock as well as the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrant Shares and Ordinary Warrant Shares underlying the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and Common Warrants, respectively, sold to the selling stockholder, and to use commercially reasonable best efforts to cause the
registration statement to become effective within 30 days of the closing date in the event of no review by the SEC, or 45 days in the event of a review by the SEC. We agreed to use commercially reasonable best efforts to keep the registration
statement effective until the date on which all of the Securities sold in the Private Placement are sold by the selling stockholder. We are registering the shares to be sold by the selling stockholder under the registration statement of which this
prospectus is a part to satisfy our obligation under the PIPE Securities Purchase Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom423556_10"></A>PLAN OF
DISTRIBUTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Selling Shareholder (for the purposes of this section, the &#147;Selling Shareholders&#148;) of the securities and
any of their pledgees, assignees and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> may, from time to time, sell any or all of their securities covered hereby on the Nasdaq Capital Market or
any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Shareholder may use any one or more of the following methods when selling
securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the
<FONT STYLE="white-space:nowrap">broker-dealer</FONT> solicits purchasers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the <FONT STYLE="white-space:nowrap">broker-dealer</FONT> will attempt to sell the
securities as agent but may position and resell a portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a <FONT STYLE="white-space:nowrap">broker-dealer</FONT> as principal and resale by the <FONT
STYLE="white-space:nowrap">broker-dealer</FONT> for its account; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">settlement of short sales; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in transactions through <FONT STYLE="white-space:nowrap">broker-dealers</FONT> that agree with the Selling
Shareholders to sell a specified number of such securities at a stipulated price per security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Shareholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if
available, rather than under this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Broker-dealers</FONT> engaged by the Selling Shareholders
may arrange for other <FONT STYLE="white-space:nowrap">brokers-dealers</FONT> to participate in sales. <FONT STYLE="white-space:nowrap">Broker-dealers</FONT> may receive commissions or discounts from the Selling Shareholders (or, if any <FONT
STYLE="white-space:nowrap">broker-dealer</FONT> acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in
excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of the securities or interests therein, the Selling Shareholders may enter into hedging transactions with
broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Shareholders may also sell securities short and deliver these securities to
close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Shareholders may also enter into option or other transactions with broker-dealers or other financial institutions
or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell
pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Shareholders and any broker-dealers or
agents that are involved in selling the securities may be deemed to be &#147;underwriters&#148; within the meaning of the Securities Act in connection with such sales. In such event, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the
Securities Act. Each Selling Shareholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company
has agreed to indemnify the Selling Shareholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We agreed to keep this prospectus effective until the earlier of (i)&nbsp;the date on which the securities may be resold by the Selling
Shareholders without registration and without regard to any volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> limitations by reason of Rule 144, without the requirement for the Company to be in
compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii)&nbsp;all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any
other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not
be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not
simultaneously engage in market making activities with respect to the ordinary shares for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Shareholders will be
subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the ordinary shares by the Selling Shareholders or any other person. We will
make copies of this prospectus available to the Selling Shareholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the
Securities Act). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom423556_11"></A>EXPENSES RELATED TO THIS OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The costs and expenses payable by the Company in connection with the offerings described in this registration statement are set forth below.
The selling stockholder will not bear any portion of such expenses. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printer costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated as permitted under Rule 511 of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom423556_12"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities offered by this prospectus and other legal matters concerning this offering relating to Cayman Islands law will
be passed upon for us by Ogier. Certain legal matters relating to U.S. law will be passed upon for us by Loeb&nbsp;
&amp; Loeb LLP. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom423556_13"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Virax Biolabs Group Limited as of March&nbsp;31, 2022, and 2021 and for the years then ended, have
been incorporated by reference herein in reliance upon the report of BF Borgers CPA PC, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registered business address of BF Borgers CPA PC is 5400 W Cedar Ave, Lakewood, CO 80226, United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom423556_14"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus the information in documents we file with it. This means that
we can disclose important information to you by referring you to another document filed by us with the SEC. Each document incorporated by reference is current only as of the date of such document, and the incorporation by reference of such documents
shall not create any implication that there has been no change in our affairs since the date thereof or that the information contained therein is current as of any time subsequent to its date. The information incorporated by reference is considered
to be a part of this prospectus and should be read with the same care. When we update the information contained in documents that have been incorporated by reference by making future filings with the SEC, the information incorporated by reference in
this prospectus is considered to be automatically updated and superseded. In other words, in the case of a conflict or inconsistency between information contained in this prospectus and information incorporated by reference into this prospectus, you
should rely on the information contained in the document that was filed later. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate by reference into this prospectus documents
listed below and any future filings made with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, and, to the extent specifically designated therein, reports on Form <FONT STYLE="white-space:nowrap">6-K</FONT> we furnish to the SEC
on or after the date on which this registration statement is first filed with the SEC and until the termination or completion of that offering under this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1885827/000095017022017130/vrax-20220331.htm">Form
 <FONT STYLE="white-space:nowrap">20-F</FONT></A> for the fiscal year ended December&nbsp;31, 2022, filed with the SEC on August&nbsp;12, 2022; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Reports of Foreign Private Issuer on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> furnished to the SEC
on <A HREF="http://www.sec.gov/Archives/edgar/data/1885827/000095017022018162/hcw_conference_9.6.22.htm">September&nbsp;
7, 2022</A>; <A HREF="http://www.sec.gov/Archives/edgar/data/1885827/000095017022018317/hcw_conference_9.12.22.htm">September&nbsp;
12, 2022</A>; <A HREF="http://www.sec.gov/Archives/edgar/data/1885827/000095017022018651/6-k_monkeypox_antigen_9.htm">September&nbsp;20, 2022</A> (including the information contained in Exhibit 99.1 thereto, but excluding quotes of our senior
management), <A HREF="http://www.sec.gov/Archives/edgar/data/1885827/000095017022018742/6-k_cosmos_9.22.22.htm">September&nbsp;22, 2022</A> (including the information contained in Exhibit 99.1 thereto, but excluding quotes of our senior management);
<A HREF="http://www.sec.gov/Archives/edgar/data/1885827/000095017022020103/6-k_analytic_perf_10.25.htm">October&nbsp;
26, 2022</A> (including the information contained in Exhibit 99.1 thereto, but excluding quotes of our senior management); <A HREF="http://www.sec.gov/Archives/edgar/data/1885827/000095017022021570/6-k_triple_test_11.03.22.htm">November&nbsp;3,
2022</A> (including the information contained in Exhibit 99.1 thereto, but excluding quotes of our senior management), <A HREF="http://www.sec.gov/Archives/edgar/data/1885827/000095017022023305/6-k_pr_pipe_11.04.22.htm">November&nbsp;
8, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1885827/000095017022025152/6-k_richard_pallin_11.15.htm">November&nbsp;15, 2022</A> (including the information contained in Exhibit 99.1 thereto, but excluding quotes of our senior
management, and <A HREF="http://www.sec.gov/Archives/edgar/data/1885827/000095017022025459/6-k_nelson_haight_11.17.htm">November 18, 2022</A>; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our ordinary shares contained under the heading &#147;Item 1. Description of Registrant&#146;s
Securities to be Registered&#148; in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1885827/000121390022036073/ea162180-8a12b_viraxbio.htm">Form <FONT STYLE="white-space:nowrap">8-A</FONT></A>, as filed with the SEC on
June&nbsp;30, 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained herein or in a document all or a portion of which is incorporated or deemed
to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to
be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless expressly incorporated by reference, nothing in this prospectus shall be deemed to incorporate by reference information furnished to,
but not filed with, the SEC. Copies of all documents incorporated by reference in this prospectus, other than exhibits to those documents unless such exhibits are specially incorporated by reference in this prospectus, will be provided at no cost to
each person, including any beneficial owner, who receives a copy of this prospectus on the written or oral request of that person made to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Virax Biolabs Group Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>30 Broadwick Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>London, W1F 8LX </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>United
Kingdom </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: <U>info@viraxbiolabs.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom423556_15"></A>ENFORCEMENT OF CIVIL LIABILITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an exempted company with limited liability incorporated under the laws of the Cayman Islands and our affairs are governed by our second
amended and restated memorandum and articles of association and the Companies Act, and the common law of the Cayman Islands. We are incorporated in the Cayman Islands because of certain benefits associated with being a Cayman Islands company, such
as political and economic stability, an effective judicial system, a favorable tax system, the absence of foreign exchange control or currency restrictions and the availability of professional and support services. However, certain disadvantages
accompany incorporation in the Cayman Islands. These disadvantages include, but are not limited to, the following: (i)&nbsp;the Cayman Islands has a less developed body of securities laws as compared to the United States and provides less protection
for investors; and (ii)&nbsp;Cayman Islands companies may not have standing to sue before the federal courts of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Substantially all of our assets are located outside the United States. In addition, most of our directors and executive officers are nationals
or residents of jurisdictions other than the United States and substantially all of their assets are located outside the United States. As a result, it may be difficult or impossible for you to effect service of process within the United States upon
us or these persons, or to enforce judgments obtained in U.S. courts against us or them, including judgments predicated upon the civil liability provisions of the securities laws of the United States or any state in the United States. It may also be
difficult for you to enforce judgments obtained in U.S. courts based on the civil liability provisions of the U.S. federal securities laws against us and our executive officers and directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have appointed Cogency Global Inc. as our agent to receive service of process with respect to any action brought against us in the United
States in connection with this offering under the federal securities laws of the United States or of any State in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cayman Islands
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have been advised by Ogier, our counsel as to Cayman Islands law, there is uncertainty as to whether the courts of the Cayman
Islands would: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recognize or enforce judgments of U.S. courts obtained against us or our directors or officers predicated upon
the civil liability provisions of securities laws of the United States or any state in the United States; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">entertain original actions brought in each respective jurisdiction against us or our directors or officers
predicated upon the securities laws of the United States or any state in the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also been advised
by Ogier that it is uncertain whether the courts of the Cayman Islands will allow shareholders of our company to originate actions in the Cayman Islands based upon securities laws of the United States. In addition, there is uncertainty with regard
to Cayman Islands law related to whether a judgment obtained from the U.S. courts under civil liability provisions of U.S. securities laws will be determined by the courts of the Cayman Islands as penal or punitive in nature. If such a determination
is made, the courts of the Cayman Islands will not recognize or enforce the judgment against a Cayman Islands company, such as our company. As the courts of the Cayman Islands have yet to rule on making such a determination in relation to judgments
obtained from U.S. courts under civil liability provisions of U.S. securities laws, it is uncertain whether such judgments would be enforceable in the Cayman Islands. Ogier has further advised us that although there is no statutory enforcement in
the Cayman Islands of judgments obtained in the United States, the courts of the Cayman Islands will recognize and enforce a foreign judgement, without any <FONT STYLE="white-space:nowrap">re-examination</FONT> or
<FONT STYLE="white-space:nowrap">re-litigation</FONT> of matters adjudicated upon, provided such judgment: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is given by a foreign court of competent jurisdiction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">imposes on the judgment debtor a liability to pay a liquidated sum for which the judgment has been given;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is final; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is not in respect of taxes, a fine or a penalty; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">was not obtained by fraud; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is not of a kind the enforcement of which is contrary to natural justice or the public policy of the Cayman
Islands. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of all of the above, public shareholders may have more difficulty in protecting
their interests in the face of actions taken by management, members of the board of directors or controlling shareholders than they would as public shareholders of a U.S. company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Singapore </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Singapore has no arrangement
for the reciprocal enforcement of judgments with the United States. It is possible that the Singapore courts may not (i)&nbsp;recognize and enforce judgments of courts in the United States, based upon the civil liability provisions of the securities
laws of the United States or any state or territory of the United States, or (ii)&nbsp;enter judgments in original actions brought in the Singapore courts based solely on the civil liability provisions of these securities laws. An in <I>personam</I>
final and conclusive judgment in the federal or state courts of the United States under which a fixed or ascertainable sum of money is payable may generally be enforced as a debt in the Singapore courts under the common law as long as it is
established that the Singapore courts have jurisdiction over the judgment debtor, subject to the applicable substantive and procedural laws of Singapore. Additionally, the court where the judgment was obtained must have had international
jurisdiction over the party sought to be bound in the local proceedings. However, the Singapore courts are unlikely to enforce a foreign judgment if (a)&nbsp;the foreign judgment is inconsistent with a prior local judgment that is binding on the
same parties; (b)&nbsp;the enforcement of the foreign judgment would contravene the public policy of Singapore; (c)&nbsp;the proceedings in which the foreign judgment was obtained were contrary to principles of natural justice; (d)&nbsp;the foreign
judgment was obtained by fraud; or (e)&nbsp;the enforcement of the foreign judgment amounts to the direct or indirect enforcement of a foreign, penal, revenue or other public laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, the Singapore courts may potentially not allow the enforcement of any foreign judgment for a sum payable in respect of taxes,
fines, penalties or other similar charges, including the judgments of courts in the United States based upon the civil liability provisions of the securities laws of the United States or any state or territory of the United States. In respect of
civil liability provisions of the United States federal and state securities law which permit punitive damages against us and our Directors or Executive Officers, we are unaware of any decision by the Singapore courts which has considered the
specific issue of whether a judgment of a United States court based on such civil liability provisions of the securities laws of the United States or any state or territory of the United States is enforceable in Singapore. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Hong Kong </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is uncertainty as to
whether the courts of Hong Kong would (i)&nbsp;recognize or enforce judgments of United States courts obtained against us or our directors or officers predicated upon the civil liability provisions of the securities laws of the United States or any
state in the United States or (ii)&nbsp;entertain original actions brought in Hong Kong against us or our directors or officers predicated upon the securities laws of the United States or any state in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A judgment of a court in the United States predicated upon U.S. federal or state securities laws may be enforced in Hong Kong at common law by
bringing an action in a Hong Kong court on that judgment for the amount due thereunder, and then seeking summary judgment on the strength of the foreign judgment, provided that the foreign judgment, among other things, is (1)&nbsp;for a debt or a
definite sum of money (not being taxes or similar charges to a foreign government taxing authority or a fine or other penalty) and (2)&nbsp;final and conclusive on the merits of the claim, but not otherwise. Such a judgment may not, in any event, be
so enforced in Hong Kong if (a)&nbsp;it was obtained by fraud; (b)&nbsp;the proceedings in which the judgment was obtained were opposed to natural justice; (c)&nbsp;its enforcement or recognition would be contrary to the public policy of Hong Kong;
(d)&nbsp;the court of the United States was not jurisdictionally competent; or (e)&nbsp;the judgment was in conflict with a prior Hong Kong judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Hong Kong has no arrangement for the reciprocal enforcement of judgments with the United States. As a result, there is uncertainty as to the
enforceability in Hong Kong, in original actions or in actions for enforcement, of judgments of United States courts of civil liabilities predicated solely upon the federal securities laws of the United States or the securities laws of any State or
territory within the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>China </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is uncertainty as to whether the courts of China would (1)&nbsp;recognize or enforce judgments of United States courts obtained against
us or such persons predicated upon the civil liability provisions of the securities laws of the United States or any state thereof, or (2)&nbsp;be competent to hear original actions brought in each respective jurisdiction, against us or such persons
predicated upon the securities laws of the United States or any state thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The recognition and enforcement of foreign judgments are mainly provided for under the
Chinese Civil Procedure Law. Chinese courts may recognize and enforce foreign judgments in accordance with the requirements of the Chinese Civil Procedure Law and other applicable laws and regulations based either on treaties between China and the
country where the judgment is made or in reciprocity between jurisdictions. Accordingly, there is uncertainty whether China courts will recognize or enforce judgments of United States or Cayman Islands Courts because China does not have any treaties
or other agreements with the Cayman Islands or the United States that provide for the reciprocal recognition and enforcement of foreign judgments as of the date of this prospectus. Further, under Chinese Civil Procedure Law, Chinese courts will not
enforce a foreign judgment against us or our officers and directors if the court decides that such judgment violates the basic principles of PRC law or national sovereignty, security or social public interest. As a result, it is uncertain whether
and on what basis a PRC court would enforce a judgment rendered by a court in the United States or in the Cayman Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the PRC
Civil Procedure Law, foreign shareholders may originate actions based on PRC law against a company in China for disputes if they can establish sufficient nexus to the PRC for a PRC court to have jurisdiction, and meet other procedural requirements,
including, among others, the plaintiff must have a direct interest in the case, and there must be a concrete claim, a factual basis and a cause for the suit. However, it will be difficult for U.S. shareholders to originate actions against us in the
PRC in accordance with PRC laws because we are incorporated under the laws of the Cayman Islands and it will be difficult for U.S. shareholders, by virtue only of holding our ordinary shares, to establish a connection to the PRC for a PRC court to
have jurisdiction as required under the PRC Civil Procedure Law. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom423556_16"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">F-1,</FONT> including amendments and
relevant exhibits and schedules, under the Securities Act covering the Ordinary Shares to be sold in this offering. This prospectus, which constitutes a part of the registration statement, summarizes material provisions of contracts and other
documents that we refer to in the prospectus. Since this prospectus does not contain all of the information contained in the registration statement, you should read the registration statement and its exhibits and schedules for further information
with respect to us and our Ordinary Shares. Our SEC filings, including the registration statement, are also available to you on the SEC&#146;s website at http://www.sec.gov. The SEC maintains a website (http://www.sec.gov) that contains reports,
proxy and information statements and other information regarding registrants that file electronically with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the
information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those requirements we file reports with the SEC. Those other reports or other information may be inspected without charge at the
locations described above. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the
reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as
frequently or as promptly as United States companies whose securities are registered under the Exchange Act. However, we file with the SEC, within four months after the end of each fiscal year, or such applicable time as required by the SEC, an
annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> containing financial statements audited by an independent registered public accounting firm, and submit to the SEC, on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> unaudited
quarterly financial information for the first three quarters of each fiscal year within 60 days after the end of each such quarter, or such applicable time as required by the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a principal website at <I>https://viraxbiolabs.com/</I>. Information contained on, or that can be accessed through, our website is
not a part of, and shall not be incorporated by reference into, this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:40pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g423556g33s03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Virax Biolabs Group Limited </B></P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary Shares </B></P> <P STYLE="font-size:150pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:250pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022 </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;6. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second amended and restated memorandum and articles of association empowers us to indemnify our directors and officers against certain
liabilities they incur by reason of their being a director or officer of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements
with each of our directors and executive officers in connection with this offering. Under these agreements, we have agreed to indemnify our directors and executive officers against certain liabilities and expenses incurred by such persons in
connection with claims made by reason of their being a director or officer of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting agreement in connection with
this offering also provides for indemnification of us and our officers, directors or persons controlling us for certain liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
intend to obtain directors&#146; and officer&#146;s liability insurance coverage that will cover certain liabilities of directors and officers of our company arising out of claims based on acts or omissions in their capacities as directors or
officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7. Recent Sales of Unregistered Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding ordinary shares issued by us during the last three years. None of the below described transactions
involved any underwriters, underwriting discounts and commissions or commissions, or any public offering. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On September&nbsp;2, 2021, we issued one class B ordinary share to Ogier Global Subscriber (Cayman) Limited at
par value, which was subsequently transferred to James Alexander Cunliffe Foster on 7&nbsp;September 2021. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On September&nbsp;24, 2021, we issued an aggregate of 2,549,028 class A ordinary shares to the following
shareholders in exchange for their shares held in Virax Biolabs Limited to be transferred to our wholly owned subsidiary, Virax Biolabs (UK) Limited: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Class A<BR>ordinary<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rudiger Gisbert Paul Hausherr</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">H&amp;P Facilities Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rowan Kenley Johnston</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kasin Pte. Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KOMODO HOLDINGS (ALBERTA) ULC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Lawrence Liebe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary Lance Monson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jay Eliot Newby</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pacific Frontier Investments LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Friedrich Heinz Hermann Panning</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Darold H Parken</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nikolas Perrault</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lawrence Young Rhee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Roukounakis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sam Dimas Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Seraph Holdings Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason Gerald Shenk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">713,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alex Lucas Smayda</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">STBS Consultants Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ranjeet Sundher</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Class A<BR>ordinary<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Fitzgerald Thornton</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Veritas Holdings LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VIRALCLEAR RAPID TEST CORP.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">374,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin James Youngman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Michael Betsalel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory D L Braun</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arthur Thomas Brock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sebastien Chaumet</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dunster 22 Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George James Feiss III</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Henry Cunliffe Foster</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">737,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fiona Elizabeth Cunliffe Foster</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anne Rosemary Scott Foster</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ian Denis Gee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Katherine Nahon Gordon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gralex Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On September&nbsp;24, 2021, we also issued an aggregate of 7,034,305 class B ordinary shares to the following
shareholders in exchange for their shares held in Virax Biolabs Limited to be transferred to our wholly owned subsidiary, Virax Biolabs (UK) Limited: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Class B<BR>ordinary<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Alexander Cunliffe Foster</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,515,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tomasz Evan George</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cameron Lee Shaw</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,258,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark James Ternouth</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">James Alexander Cunliffe Foster and Cameron Lee Shaw subsequently transferred an aggregate of 666,338 class B
ordinary shares and 1,154,989 class B ordinary shares, respectively, to other parties on the same day. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On October&nbsp;11, 2021, we issued 7,547 class A ordinary shares to Ian Noel Hampson upon conversion of an
aggregate of 7,547 class B ordinary shares that was transferred to him from James Alexander Cunliffe Forster and Cameron Lee Shaw. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On December&nbsp;9, 2021, we issued an aggregate of 279,432 class A ordinary shares to the following
shareholders by capitalization of loans assigned to the Company by these shareholders: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Class A<BR>ordinary<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Alexander Cunliffe Foster</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anne Rosemary Scott Foster</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Henry Cunliffe Foster</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cameron Lee Shaw</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On December&nbsp;13, 2021, we issued 33,962 class A ordinary shares to the following shareholders at US$2.65
per share by way of transferring treasury shares held by the Company that resulted from the surrender of 50,000 class A ordinary shares held by Viralclear Rapid Test Corp. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Class A<BR>ordinary<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc Frouin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bruce S. Lavin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Karen A Bertoli</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On December&nbsp;17, 2021, Patrick Henry Cunliffe Foster surrendered 109,412 class A ordinary shares to the
Company for cancellation. On the same day, we issued 21,697 class A ordinary shares to Jason Gerald Shenk and on the same day transferred to him an additional 16,038 class A ordinary shares which was held as treasury shares by the Company at US$2.65
per share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On January&nbsp;5, 2022, we issued an aggregate of 201,500 class A ordinary shares to the following
shareholders at US$2.65 per share: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Class A<BR>ordinary<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adewale Adegbenro</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan Bastien</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alberto Galeone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Luc Grenier</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Jones</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phillip Joseph</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gino Masciotra</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salvatore Mendolia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilbert Payeur</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9332-2808 Quebec Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Louis Sanzo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anthony Verelli</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On March&nbsp;18, 2022, James Alexander Cunliffe Foster and Cameron Lee Shaw subsequently transferred an
aggregate of 83,000 class B ordinary shares, to BGGF Limited and as a result of the automatic conversion, BGGF Limited received 83,000 class A ordinary shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On May&nbsp;10, 2022, we issued 7,547 class A ordinary shares to Laith Yakob at US$2.65 per share.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On May&nbsp;13, 2022, we issued 40,000 class A ordinary shares to Thomas Bolther at US$2.65 per share.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On June&nbsp;3, 2022, Anne Rosemary Scott Foster, Ann Mary Catherine Shaw, Alexander Tarrant Shaw, Michael Shaw
and Giuseppe Capozzo have requested to convert an aggregate of 1,821,327 class B ordinary shares into class A ordinary shares on a 1 to 1 basis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On June&nbsp;19, 2022, James Foster, Tomasz George, Cameron Shaw and Mark Ternouth have requested to convert an
aggregate of 5,122,432 class B ordinary shares into class A ordinary shares on a 1 to 1 basis, as a result, the Company has an issued share capital of 10,024,098 class A ordinary shares. On the same date, the Company underwent a shareholding
restructuring whereby the Company&#146;s dual class share capital was amended to a single class of Ordinary Shares and all of the class A ordinary shares was <FONT STYLE="white-space:nowrap">re-designated</FONT> as Ordinary Shares.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;3, 2022, the Company entered into a Securities Purchase Agreement (the &#147;PIPE Securities Purchase
Agreement&#148;) with an accredited investor (the &#147;Purchaser&#148;) for a private placement offering (&#147;Private Placement&#148;), pursuant to which the Company received gross proceeds of approximately $3,844,500, before deducting placement
agent fees and other offering expenses, in consideration of (i)1,165,000 ordinary shares; (b) 1,165,000 <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants <FONT STYLE="white-space:nowrap">(&#147;Pre-Funded</FONT> Warrants&#148;), and (iii)
3,495,000 warrants (&#147;Ordinary Warrants&#148;) at a combined purchase price of $1.65 per ordinary shares are and one and a half Ordinary Warrant, or approximately $1.65 per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant and one and a
half Ordinary Warrant if purchasing the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. The Private Placement closed on November&nbsp;8, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the offers, sales and issuances of the securities described in the preceding paragraph were exempt from registration either
(a)&nbsp;under Section&nbsp;4(a)(2) of the Securities Act and the rules and regulations promulgated thereunder, in that the transactions were between an issuer and sophisticated investors or members of its senior executive management and did not
involve any public offering within the meaning of Section&nbsp;4(a)(2), (b) under Regulation S promulgated under the Securities Act in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts
were made in the United States, or (c)&nbsp;under Rule 701 promulgated under the Securities Act in that the transactions were underwritten compensatory benefit plans or written compensatory contracts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8. Exhibits and Financial Statement Schedules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) Exhibits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the Exhibit Index
attached to this registration statement, which is incorporated by reference herein. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b) Financial Statement Schedules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Schedules have been omitted because the information required to be set forth therein is not applicable or has been included in the consolidated
financial statements or notes thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9. Undertakings. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The undersigned registrant hereby undertakes: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To file, during any period in which offers or sales are being made, a post-effective amendment to this
registration statement: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To include any prospectus required by section 10(a)(3) of the Securities Act of 1933; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect in the prospectus any facts or events arising after the effective date of the registration statement
(or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of
securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate
offering price set forth in the &#147;Calculation of Registration Fee&#148; table in the effective registration statement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To include any material information with respect to the plan of distribution not previously disclosed in the
registration statement or any material change to such information in the registration statement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective
amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To remove from registration by means of a post-effective amendment any of the securities being registered which
remain unsold at the termination of the offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To file a post-effective amendment to the registration statement to include any financial statements required
by Item 8.A. of Form <FONT STYLE="white-space:nowrap">20-F</FONT> at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section&nbsp;10(a)(3) of the Act need not be
furnished, provided that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all other information in the
prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, with respect to registration statements on Form <FONT STYLE="white-space:nowrap">F-3,</FONT> a post-effective amendment need not be filed to
include financial statements and information required by Section&nbsp;10(a)(3) of the Act if such financial statements and information are contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to section
13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Form <FONT STYLE="white-space:nowrap">F-3.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the registrant is relying on Rule 430B: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the
registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration
statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and
included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule
430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that
prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective
date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a
registration statement relating to an offering, other than registration statements relying on </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness.
Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that
is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
statement or made in any such document immediately prior to such date of first use. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any
purchaser in the initial distribution of the securities the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used
to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell
such securities to such purchaser: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be
filed pursuant to Rule 424; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or
used or referred to by the undersigned registrant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The portion of any other free writing prospectus relating to the offering containing material information about
the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the
underwriting agreements, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors,
officers and controlling persons of the registrant pursuant to the provisions described in Item 6 hereof, or otherwise, the registrant has been advised that in the opinion of the U.S. Securities and Exchange Commission such indemnification is
against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director,
officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be
governed by the final adjudication of such issue. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The undersigned registrant hereby undertakes that: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For purposes of determining any liability under the Securities Act, the information omitted from the form of
prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of
this registration statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of determining any liability under the Securities Act, each post-effective amendment that
contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide </I>offering thereof.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit <BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description of
Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001885827/000121390022033728/ff12022a4ex3-1_viraxbiolabs.htm">Second Amended and Restated Memorandum and Articles of Association, as currently in effect (filed as Exhibit 3.1 to Amendment
 No.&nbsp;6 to the Registrant&#146;s registration statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-263694),</FONT> filed with the SEC on June&nbsp;27, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001885827/000121390022033728/ff12022a4ex4-1_viraxbiolabs.htm">Specimen certificate evidencing Ordinary Shares (filed as Exhibit 4.1 to the Registrant&#146;s registration statement on Form
 <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-263694),</FONT> filed with the SEC on March&nbsp;18, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1885827/000095017022023305/vrax-ex10_4.htm">Pre-Funded Ordinary Share Purchase Warrant (filed as Exhibit 10.4 to the Registrant&#146;s report of foreign private issuer on Form 6-K (File No.
 <FONT STYLE="white-space:nowrap">(001-41440))</FONT> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1885827/000095017022023305/vrax-ex10_2.htm">Ordinary Share Purchase Warrant (filed as Exhibit 10.2 to the Registrant&#146;s report of foreign private issuer on Form 6-K (File No. <FONT
STYLE="white-space:nowrap">(001-41440))</FONT> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d423556dex51.htm">Opinion of Ogier </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1885827/000095017022023305/vrax-ex10_1.htm">Securities Purchase Agreement dated November&nbsp;
3, 2022 (filed as Exhibit 10.1 to the Registrant&#146;s report of foreign private issuer on Form 6-K (File No. <FONT STYLE="white-space:nowrap">(001-41440))</FONT> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1885827/000095017022023305/vrax-ex10_3.htm">Registration Rights Agreement dated November&nbsp;
3, 2022 (filed as Exhibit 10.3 to the Registrant&#146;s report of foreign private issuer on Form 6-K (File No. <FONT STYLE="white-space:nowrap">(001-41440))</FONT> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d423556dex211.htm">List of Subsidiaries </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d423556dex231.htm">Consent of BF Borgers CPA PC, an independent registered public accounting firm </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d423556dex51.htm">Consent of Ogier (included in Exhibit 5.1) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d423556dexfilingfees.htm">Calculation of Registration Fee </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">F-1</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in London, United Kingdom,
on November&nbsp;18, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VIRAX BIOLABS GROUP LIMITED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ James Foster</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Name: James Foster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KNOW ALL MEN BY THESE PRESENTS that each person whose signature appears below hereby constitutes and appoints James Foster and Jason Davis,
and each of them, his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power to act separately and full power of substitution and resubstitution, for him
or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement and all additional registration statements pursuant to Rule 462(b) of the
Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the SEC, granting unto each said
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents or either of them or his or her or their substitute or substitutes may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the
capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ James Foster</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">James Foster</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal executive
officer) and Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">November&nbsp;18, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Jason Davis</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jason Davis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal financial
and accounting officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">November&nbsp;18, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Cameron Shaw</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Cameron Shaw</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director and Chief Operating Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">November&nbsp;18, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Yair Erez</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Yair Erez</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Independent Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">November&nbsp;18, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Evan Norton</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Evan Norton</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Independent Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">November&nbsp;18, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Nelson Haight</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Nelson Haight</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Independent Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">November&nbsp;18, 2022</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AUTHORIZED REPRESENTATIVE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Virax Biolabs Group Limited
has signed this registration statement on November&nbsp;18, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Virax Biolabs Group Limited</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Nelson Haight</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Name: Nelson Haight</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title: Director</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-10 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d423556dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Virax Biolabs Group Limited</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o&#151;Ogier Global (Cayman) Limited</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">89 Nexus Way, Camana
Bay</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Grand Cayman <FONT STYLE="white-space:nowrap">KY1-9009</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Cayman Islands</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>D +852 3656 6061</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>E florence.chan@ogier.com</B></P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference: FYC/JNG/500373.00003</P> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">18&nbsp;November 2022</P></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Virax Biolabs Group Limited (the Company) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as Cayman Islands counsel to the Company in connection with the Company&#146;s registration statement on Form
<FONT STYLE="white-space:nowrap">F-1,</FONT> including all amendments or supplements thereto (the <B>Registration Statement</B>), as filed with the United States Securities and Exchange Commission (the <B>Commission</B>) under the United States
Securities Act 1933, as amended (the <B>Act</B>) on or about the date hereof. The Registration Statement relates to the resale by certain selling shareholders of the Company as stated in the Registration Statement (collectively, the <B>Selling
Shareholders</B>) of up to 5,825,000 ordinary shares of US$0.0001 par value each of the Company (the <B>Ordinary Shares</B>) which are presently issued and outstanding (the <B>Resale Shares</B>). The Resale Shares are comprised of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">1,165,000 Ordinary Shares (the <B>PIPE Shares</B>) issued pursuant to the securities purchase agreement, dated
as of November&nbsp;3, 2022, by and between Armistice Capital Master Fund Ltd. (the <B>PIPE Securities Purchase Agreement</B>); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">1,165,000 Ordinary Shares (the <B><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares</B>) issued
or issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (the <B><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</B>) that were issued pursuant to the PIPE Securities Purchase Agreement; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">3,495,000 Ordinary Shares (the <B>Warrant Shares</B>) issued or issuable upon the exercise of ordinary warrants
(the <B>Ordinary Warrants</B>) that were issued pursuant to the PIPE Securities Purchase Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless a contrary intention
appears, all capitalised terms used in this opinion have the respective meanings set forth in the Documents. A reference to a Schedule is a reference to a schedule to this opinion and the headings herein are for convenience only and do not affect
the construction of this opinion. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="54%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Ogier</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">British Virgin Islands,
Cayman Islands, Guernsey,<BR>Jersey and Luxembourg practitioners</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Floor 11 Central Tower</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">28 Queen&#146;s Road Central</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Central</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Hong Kong</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">T +852 3656 6000</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">F +852 3656 6001</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>ogier.com</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Partners</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Nicholas Plowman</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Nathan Powell</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Anthony Oakes</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Oliver Payne</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Kate Hodson</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">David Nelson</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Michael Snape</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Justin Davis</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Florence Chan</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Lin Han</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Cecilia Li</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">James Bergstrom</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Marcus
Leese</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Documents examined </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the purposes of giving this opinion, we have examined originals, copies, or drafts of the following documents: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the certificate of incorporation of the Company dated 2&nbsp;September 2021 issued by the Registrar of
Companies of the Cayman Islands (the <B>Registrar</B>) and a certificate of incorporation on change of name dated 19&nbsp;January 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the second amended and restated memorandum and articles of association of the Company filed with the Registrar
on 19&nbsp;June 2022 (the <B>Memorandum</B> and <B>Articles</B>); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a certificate of good standing dated 22&nbsp;July 2022 (the <B>Good Standing Certificate</B>) issued by the
Registrar in respect of the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the register of directors and officers of the Company as at 6&nbsp;June 2022 (the <B>Register of
Directors</B>); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the listed register of members of the Company downloaded from the website
<FONT STYLE="white-space:nowrap">&lt;https://cstt.citrixdata.com/d-s671642f3b570438d8fb2a32d1440912c&gt;</FONT> on 7&nbsp;November 2022 showing the issued share capital as 11,576,598 ordinary shares (the <B>Listed Register of Members</B>, and
together with the Register of Directors, the <B>Registers</B>); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a certificate dated 18&nbsp;November 2022 as to certain matters of fact signed by a director of the Company
(the <B>Director&#146;s Certificate</B>), having attached to it a copy of the minutes of the board meeting of the Company held on 7&nbsp;November 2022 (the <B>Board Minutes</B>); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the PIPE Securities Purchase Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Ordinary Warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants<B> </B>(and together with the PIPE Securities
Purchase Agreement and the Ordinary Warrants, the<B> Documents</B>); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Registration Statement. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assumptions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In giving this opinion we have relied upon the assumptions set forth in this paragraph 2 without having carried out any independent
investigation or verification in respect of those assumptions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all original documents examined by us are authentic and complete; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all copy documents examined by us (whether in facsimile, electronic or other form) conform to the originals and
those originals are authentic and complete; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all signatures, seals, dates, stamps and markings (whether on original or copy documents) are genuine;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each of the Good Standing Certificate, the Registers and the Director&#146;s Certificate is accurate and
complete as at the date of this opinion; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all copies of the Registration Statement are true and correct copies and the Registration Statement conform in
every material respect to the latest drafts of the same produced to us and, where the Registration Statement has been provided to us in successive drafts <FONT STYLE="white-space:nowrap">marked-up</FONT> to indicate changes to such documents, all
such changes have been so indicated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the resolutions passed at the board meeting as documented in the Board Minutes remains in full force and effect
and each of the directors of the Company has acted in good faith with a view to the best interests of the Company and has exercised the standard of care, diligence and skill that is required of him or her in approving the transaction and no director
has a financial interest in or other relationship to a party of the transactions contemplated by the Documents which has not been properly disclosed in the Board Minutes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">neither the directors and shareholders of the Company have taken any steps to appoint a liquidator of the
Company and no receiver has been appointed over any of the Company&#146;s property or assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the maximum number of Ordinary Shares to be issued by the Company under the Documents would not exceed the
Company&#146;s authorised share capital and the consideration payable for each Ordinary Share shall be no less than the par value of US$0.0001 each; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">there is no provision of the law of any jurisdiction, other than the Cayman Islands, which would have any
implication in relation to the opinions expressed herein. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Opinions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On the basis of the examinations and assumptions referred to above and subject to the qualifications and the limitations set forth below, we
are of the opinion that: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Corporate status </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has been duly incorporated as an exempted company and is validly existing and in good standing with
the Registrar of Companies of the Cayman Islands (the <B>Registrar</B>). </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Valid Issuance of Resale Shares </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The PIPE Shares being proposed for resale by the Selling Shareholders have been validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares and Warrant Shares to be issued pursuant
to the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the Ordinary Warrants, respectively, have been duly authorised for issue and when: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issued by the Company upon due exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and
the Ordinary Warrants in accordance with the Registration Statement, the Documents and the duly passed resolutions as set out in the Board Minutes and once consideration as stated in the Documents which shall not be less than the par value per <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares or Warrant Shares (as the case may be) is paid; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such issuance of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares and Warrant Shares have been
duly registered in the Company&#146;s register of members as fully paid shares, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">will be validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Limitations and Qualifications </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We offer no opinion: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as to any laws other than the laws of the Cayman Islands, and we have not, for the purposes of this opinion,
made any investigation of the laws of any other jurisdiction, and we express no opinion as to the meaning, validity, or effect of references in the Documents to statutes, rules, regulations, codes or judicial authority of any jurisdiction other than
the Cayman Islands; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">except to the extent that this opinion expressly provides otherwise, as to the commercial terms of, or the
validity, enforceability or effect of the Registration Statement, the accuracy of representations, the fulfilment of warranties or conditions, the occurrence of events of default or terminating events or the existence of any conflicts or
inconsistencies among the Registration Statement and any other agreements into which the Company may have entered or any other documents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Under the Companies Act (Revised) (<B>Companies Act</B>) of the Cayman Islands annual returns in respect of the
Company must be filed with the Registrar of Companies in the Cayman Islands, together with payment of annual filing fees. A failure to file annual returns and pay annual filing fees may result in the Company being struck off the Register of
Companies, following which its assets will vest in the Financial Secretary of the Cayman Islands and will be subject to disposition or retention for the benefit of the public of the Cayman Islands. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In <B>good standing</B> means only that as of the date of this opinion the Company is <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date</FONT></FONT> with the filing of its annual returns and payment of annual fees with the Registrar of Companies. We have made no enquiries into the Company&#146;s good standing
with respect to any filings or payment of fees, or both, that it may be required to make under the laws of the Cayman Islands other than the Companies Act. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Governing law of this opinion </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This opinion is: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">governed by, and shall be construed in accordance with, the laws of the Cayman Islands; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">limited to the matters expressly stated in it; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">confined to, and given on the basis of, the laws and practice in the Cayman Islands at the date of this
opinion. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise indicated, a reference to any specific Cayman Islands legislation is a reference to that
legislation as amended to, and as in force at, the date of this opinion. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Reliance </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to our firm under the headings
&#147;<I>Enforcement of Civil Liabilities</I>&#148; and &#147;<I>Legal Matters</I>&#148; of the Registration Statement. In giving such consent, we do not believe that we are &#147;experts&#148; within the meaning of such term used in the Securities
Act or the rules and regulations of the Commission issued thereunder with respect to any part of the Registration Statement, including this opinion as an exhibit or otherwise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This opinion may be used only in connection with the resale of the Resale Shares while the Registration Statement is effective. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours faithfully </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g423556g48s04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ogier </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>d423556dex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>List of Subsidiaries of the Registrant</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Subsidiary</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Place of Incorporation</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Virax Biolabs (UK) Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>United Kingdom</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Virax Biolabs Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Hong Kong</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Virax Biolabs USA Management, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>United States</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Virax Immune <FONT STYLE="white-space:nowrap">T-Cell</FONT> Medical Device Company
Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Hong Kong</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Virax Biolabs Pte. Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Singapore</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Logico Bioproducts Corp.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>British Virgin Islands</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shanghai Xitu Consulting Co., Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PRC</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d423556dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors of </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Virax Biolabs Group Limited </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in the Form <FONT STYLE="white-space:nowrap">F-1</FONT> Registration Statement of Virax Biolabs Group Limited
(&#147;the Company&#148;) (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-263694)</FONT> of our report dated August&nbsp;12, 2022 with respect to our audits of the consolidated statements of financial position of March&nbsp;31, 2022 and 2021,
and consolidated statements of profit and loss and other comprehensive loss, changes in equity and cash flows for the years then ended appearing in the Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> of the Company for the year
ended March&nbsp;31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also consent to the reference to us under the caption &#147;Experts&#148; in the Registration Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>/s/ BF Borgers CPA PC </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certified Public Accountants </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lakewood, Colorado </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;18, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>d423556dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">F-1</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Virax Biolabs Group Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table 1: Newly Registered and Carry Forward Securities </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000" ALIGN="center"><B>Security&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Security&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;" ALIGN="center"><B>Fee&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;" ALIGN="center"><B>Amount&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;Proposed&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;Maximum&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;" ALIGN="center"><B>Fee&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;" ALIGN="center"><B>Amount&nbsp;of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" ALIGN="center"><B>Type&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Class&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" ALIGN="center"><B>Calculation&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" ALIGN="center"><B>Registered<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;Maximum&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;Aggregate&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" ALIGN="center"><B>Rate&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" ALIGN="center"><B>Registration&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Title&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" ALIGN="center"><B>or&nbsp;Carry&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;Offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;Offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" ALIGN="center"><B>Fee&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" ALIGN="center"><B>Forward&nbsp;Rule&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;Price&nbsp;Per&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;Price<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;Unit<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" COLSPAN="31" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="30" ALIGN="center" STYLE="padding-bottom:2pt ;BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Newly Registered Securities</B></P></TD>
<TD VALIGN="top" STYLE="padding-bottom:2pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">Fees to be</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="padding-bottom:3pt ;">Equity&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Ordinary&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="padding-bottom:3pt ;">Rule&nbsp;457(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="padding-bottom:3pt ;">5,825,000&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="padding-bottom:3pt ;">$1.43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="padding-bottom:3pt ;">$8,329,750&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="padding-bottom:3pt ;">0.0001102&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="padding-bottom:3pt ;">$917.94&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">Paid</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">shares,&nbsp;par&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>value&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">US$0.0001&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">per&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">share<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="14"></TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" COLSPAN="11" NOWRAP ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000"><B>Total Offering Amounts</B></TD>
<TD VALIGN="bottom" NOWRAP STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000" ALIGN="center">$8,329,750&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000" ALIGN="center">0.0001102&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000" ALIGN="center">$917.94&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="14"></TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" COLSPAN="11" NOWRAP ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000"><B>Total Fees Previously Paid</B></TD>
<TD VALIGN="bottom" NOWRAP STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="14"></TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" COLSPAN="11" NOWRAP ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000"><B>Total Fee Offsets</B></TD>
<TD VALIGN="bottom" NOWRAP STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="14"></TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" COLSPAN="11" NOWRAP ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000"><B>Net Fee Due</B></TD>
<TD VALIGN="bottom" NOWRAP STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000" ALIGN="center">$917.94&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), the
ordinary shares being registered hereunder include such indeterminate number of ordinary shares as may be issuable with respect to such ordinary shares being registered hereunder as a result of stock splits, stock dividends or similar transactions.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) promulgated under
the Securities Act, based upon the average of the high ($1.48) and low ($1.38) prices of the ordinary shares as reported on the Nasdaq Capital Market on November&nbsp;17, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Comprised of (i) 1,165,000 PIPE Shares (as defined in the Registration Statement), (ii) 1,165,000 <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares (as defined in the Registration Statement), and (iii) 3,495,000 Warrant Shares (as defined in the Registration Statement). </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g423556g03s01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g423556g03s01.jpg
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M>'!A8VME="!E;F0](G(B/S[_[0!(4&AO=&]S:&]P(#,N,  X0DE-! 0
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M 0$            ("04'!@H  00" P$  00# 0$             !@0%!P@
M PD" 1    8! P,!!@(#"@T%     0(#! 4&!P 1""$2"1,Q05$B%!4R%F&1
M(W&!H=%"4I15%S>2TR0EE:6U-E:V)U=G=Q@X6!D1  $"!0(#!04$!08-!0
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M!*B"=.49VRCVD<V;,F+9NS9,T46S1HT1(W;-6K=,J2#9N@D4B2*"*10*0A0
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M[O\ 438.VBK8BG<._<!0'?6UNH?:45)6L*/>80UF/V6X4XI:RDI76!P"FD*
M]@(D/='L@:G7*K'IQ-8@(.N121S*)QL%%,8E@0YOQ&*T8(((%,81ZCMOKPMU
MUY6]]2E+[S&^AM-LM;(IK;3LL4_[+: @3[0$@:_9'K?P<3*&3&2BXR1](#%2
M&08M7@HE/V^H"7U"*@D _;UV$-]?$+<;)+:E)F>1E&U^@I*H 5333@2"!N0E
M4@>/$'CW1[&[-%JBFV;)(H-T2 FD@BBFDBDD4  J:2*8%3(0H>P #8->2223
MS)A0VRRTE*&DI0VD2 2) #V1B5GQK0+HH@M;Z13[2NVW!NO8ZU#3:J #MN")
MY)FY,F A[@VUO:JJE@$-.+2#V&4,MRQBP7A8=N='2ONIX*<:0LCV%0,3D-78
M6NL$HJOP\1!1B&WHQ\-'-(QBEL&P>DS9(H-T]@#W!K6ZZX^9NJ4H]Y)A?06N
MW6QGR+<PTPS.>UM"4))[2$@"/PDZC69M8CB9KL!+KII>@1Q)P\>_<$0 QC D
M19TW54*D!CB/: [;B(^_7UMUYH;6E*2GN,:ZVT6VX*"JVG8>($@5MI40.P$@
MR$2I&#8B -"MVY&94 ;%:%13!N5N! 2*@"/8"0( D';V;=O;TVVUX*B5;YG=
M/C"TT[19^GD/(V[=LA()_9V\)2Y$1B,%C#'56DG$Q6*'2Z[*N^_ZJ3A*O"1<
MBX]01,IZKYBR0<G!0YA$P";J(]=;EU52Z)..+4)2U)E#-0XMCULJ#56VBI&*
MA9FI3;2$J)[E 3'NCU*8^HZUD2N2M.JBEO1*!$K2>O1)K$D4J0HE*G-"T^Y%
M*"1A+L"OX1V]FO(J*@-^5O5L(X3TC<K';$NX_FRZ.F-R!GYOEH\R?;OENG[X
MEWM>AY)4JTE%1<BJF7TTU'\<S>*)I"/<*2:CA%0Q$Q-UV#IOUUY0XMI.UM2@
M.XR^Z%K]OH:E?F5++;JQP+B4JD#Q"9C0=T0-CQGCRWF:GM=%IMF48I@DQ4L%
M8A9@S),H !4VII!DX%NF4"@ %)VAMK8BIJ6OPG%I]AAMN&+XY=5!=RH:1]Q/
M!3C2%D=PF- .494SC&,<S081S1JP9-4RHM6;)LDU:-DB!L5-!NB4B2290]@%
M  #6DJ6M?F.*)</.'9BDIZ9D4].VA#"?E2D;0/8!*,<L6/*+;R@2V4VIV<@=
MHE+8*Y$3':8H[E$!D&C@WRC[.O36QNHJ6=&W%A/<3_BAMN..6*[B5UHZ:I'^
MU:0L_$B?VQRLX[H=+!8*?2ZG5?J!$5_R[78F&]<1#815^WM6_?OM[]>G:FI>
JD'7%*'>8RV8Y8+*"+114U-/^S;2G[A&6>B3^:7_!+_%I/(0][W.V/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g423556g13s02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g423556g13s02.jpg
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M>'!A8VME="!E;F0](G(B/S[_[0!(4&AO=&]S:&]P(#,N,  X0DE-! 0
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MD-N#_CP,F_AY?W N#?\ @]XS_@6I6!,+ 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MX%P;_P 'O&?\"U*P)A8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M]?\ %"LW,UH3[LU-*Z8:LG*>K5DX^/B#4'_9K:A(*DEU$4S>A.9,/XT5P*<
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M]N=?^#[DA^"*VX&3GP\O[@7!O_![QG_ M2L"86 P& P& P& P& P& P& P&
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M+'(:!H5A=$<>NPDS;VI5C13A=(K!TX0,U%8CDZ2:@75_T#L,'D[!#X92CV&
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M/$:_)[<Z_P#!]R0_!%;<#)SX>7]P+@W_ (/>,_X%J5@3"P& P& P& P& P&
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MO[@7!O\ P>\9_P "U*P)A8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MK[Y9NX>03:D59"%=+LUU';)P]AR101SY9B[6450,JF)DE5#'*/7I@?(&K=5
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ML:-N+<69(UTE<@J@=H]XO8(@(=[L#I[O7R=F8L=UEUT]%:]O)VZK/V9T;P,
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M K'66&/U*/IX>S1BS2P1K@.Z'0R#D@F$ [W4 Z9KP;S=8(Z+;IG''*9^6?\
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MV?/6[H" LFNJ0X'$)"X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8%N]JZFUMO"C3>L]NT:K[(UY944F]BI=RB&L[6YQNBLFX3;2D4](HT>M@53
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M0A9Q>YE[,O/([0&LH[D+6N5E)VYQ_L>QMJD)IF*T]8M%6R C8&0B3UR0B&D
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MVU;^-2O-=KJE&DEDK;XG=]J#9YM!W=[N2-0>ZBJ-E53JNO8">:[*VQ:IB69
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M^;*VAQ#L7&>U;^/(W>YZX7UC<]^/=4PKB4L,/),3Q$]-&UXVM3"$8VB7B%#
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M#T\W7 TP&!:_>7_D;N__ -%]L_@^L>!7O@F_DC?#F_PB:5_\'1V!E#P& P&
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M1(.NVMPJY1[7G^64\M&:0J9]V4+A:E1V[7:%LF>[=^*LO&6*9B;:L74L*,=
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MP)NX# 8# 8# 8# 8# UZ?Z?Z>_@LB9Q==WUM,(MF9MK=I<828# 8# 8# 8#
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MIEQISS0'A6,&EQJ5FJ+I\AR0Y0&<,FUH@W\$N[;%7TX9$[ALD_$Z8& 2B8H
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MI32;M=>N@N!#)KAT4$>^  !0#,9@,!@,!@,!@,!@,!@,!@,#3H'N!]K UP&
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ME/U[HB/3S]! /MB&!OP& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M:TI,W]J&BUV<GI*LU0T?)VA[\21KN45A6;!>1:I#,O@:G3;$<+(%]*)0,;H
M] H;0V[:WOK2>H-X1+-S48K<E*A;M 5NSR$02?CVDXB5="-=';+G9N'S B@
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M@3=P&!J ].@]1[# ;LZ /P>TO0P@8 ZCV&[!ZE$0[/+@:![XB(CTZF'M,(@
MAU$XB)Q[.SR@/3SX&H]T1 >@].WX/4  .\("8.G=[ANH_P (H]H /F[0U#M[
M  1$W;W0$0$R@B'=#J E[YU#]@=.Z'7IV=N!'"P<PN+=/G%X&X;]UG4)-*W+
MT-H6SV9G!-96[M"H&D:Q7).3%*,LD_$J.TD7K1@X<*,G)@27(FKWB8%7LN0>
MB)+:3K1L=M_6[S<[!H,@]U2UM<4XOS-B#4CP[U:J$<&DT69F2A3^F%/N"00[
M?)T"\?4P !@$#=T2#WOA'-T 0$1*'D4$W>#L#H4P]@]I1P.,Q!, %'KV"8 [
MW<Z <.O=!/O=\@].^!@#O"/?_8P-CERDT;KNW:Y6S1H@=TY<+*E(FBV;E,JX
M6.(FZE31!,QS (B/4.O0>N!&$G-GATI39K88<H]##0:U8V-1L%S/LNKC5X*W
M2IW'Q=7I:;^,"LV,])^IJ%1;*'375.EV@(_!$)*Q4I'3<7'S,(_:RD3*LFDG
M%R;-8CAA(,7B95F;QDJ4YT5FKA%8#D4*'0_>$>@CUP/K,'4!$P !!+U$?@]H
M$$H@8Y3%*8QDC=#=!#H D[3!Y,#><PD[X_\ -*0QSE* "(]"F$PB1,QS]U0"
M]I.@";KV"/7K@4?2+]3]DP(V.CS[2P0R4E)PCIPS(L@XC9N">FCYB#FF#M%N
M_B)F)D$S$7:.4TU4CCVD # &!5XB @4.@@!>@]IA$>P.Z!0$.Z8"E  Z=HC[
M_3LP'> !'H7J ]O0XB;J(F$P@(>0 'KT\X= \G41' T$0'H'4WD[>O:(CT$!
M.(AW?XP>HE[P=/@CTZ=@8 1Z_P"G[O4<#3 B1X07]\#QL?\ &KJ;\5K5N!GG
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M9ZX645,8I#$23"YY*[7$D#MDZW72-E3I**MB0,05LLHAW@056;@S!%55$IQ
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M P& P& P& P& P& P& P//ES*_+F\*_T=G+O\+FE<";N P& P& P'7_@ /V
M\@?8# 8# ?\ &'0?L=0'I]CJ'7 ?\7D_9\N P& P'E#H/D]SS8&O4>SM'L[
M]X!\P8&F P& P&!$CP@O[X'C8_XU=3?BM:MP,\^ P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P&!Y\N97Y<WA7^CLY=_A
M<TK@3=P& P& P& P& P&4ZXK37W#7IG>S%?DBME)CQ@:92DQQA%=:&0DP& P
M& P& P&!$CP@O[X'C8_XU=3?BM:MP,\^ P& P& P& P& P& P& P& P& P&
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M(=@Y@OBVW6Z&ZV[JBL.7++& P& P& P& P& P& P& P& P& P& P& P& P&
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M0,_M%KKQO7DZKHJEV5RJ2%LFV+K;[!6JY"OYA%LLO'P#9P[L4DR04<(,3(E
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M& P& P& P& P& P& P& P& P& P& P& P& P-.H>Z'^G;_P8&N P& P& P&
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MJ7C@C_\ E5.-GE .H^'="  =?)U$=T=@".!M^2?C@_G5.-@>3L'P[H0!#O%
MP"(#NCJ "40' U^2?C@_G4^-H=?=\.V% ?M#N?J& ^27C@_G5.-GZNZ$]L^!
MS-ZEXV/54DAXH_'!XV6;.FQD4/#[BXQ=(7#91NDZ:/VNYS+H.6:AP5)V" F*
M #V#V:-O.'%=&3-_$I^SP^,4<,MM^32(]NBW5)T)XQ5 *^5K_B=<:2RTNKZQ
M/6:3\/&&EK38W!A,(K3UA>;J4D7YB=[H1,3 @D7L3(0.S)W.[R[F>=F*NED3
MI'?36*JX]MCPQU6Q%U\]M/?7C[*^Q7P5'QORB/3Q4>-(![WAVPH=>G8 C_\
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M@,!@,!@,!@,!@,!@,!@,!@8X]4_EU]R?H44/QM9O ])F P& P& P& P& P&
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M%,' ])N P& P& P,#GC>?[\^#I^EITW^!#D#@2SP& P& P& P& P& P& P&
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M:@2J\E;KQ]?QEUV55T%Y%E25BHOKM6GU?9V""L<C+H."+Q\$T<J'71[Z@O
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M8?6CIA94]FR&W=:*MY=G;#.W%?LECC(385$O<ZL@F^LE$L"7K]45.W;HJ"U
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M&Y>J7P" ("80#S?!  Z (AN*5+O*+E22 ZP$!==-,@"L3M3*554I155+T)W
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MV4M28Y57O&) TR?L+ENP1,<_J[8Y4>O=(0 "</9YNO[(" ^_U >WKUP& P&
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MW*7V<X#ZXSA__(_FK] [E+[.<!]<9P__ )'\U?H'<I?9S@/KC.'_ /(_FK]
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MF*SJK=%8\$<+^=8W(SCJ((F[*YO8#=0$ ZC&4$I1Z]O0G3KV_8]WIG?;3/\
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MT)\5R;%#UN/=]Y5-3O=2X'J^P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P,#GC=_[\^#H/G^MITW^!#D#@2SP& P&
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M&UJSA)[0TY#5"?V-7",)1!.M1EZ(\-5U5)5TT1BW#F01CU3G2;JK&0#H*H$
MP=0HK>U3X^[Z3;\7-ZM#SK:\M&UXBZ*YG+K2FUS1I4F20,:'L%3FJVXGW%5D
MDT7SF,2=F42#T"ZR @"9P"_T='M(B/CXM@"Y6,8R:1[('+IR^<E:L&Y&;7T[
MUZNZ?.W*:"( 99=51=0W4YSB<QA$/LP,<>J?RZ^Y/T**'XVLW@>DS 8# 8#
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M "4"F[Q3]X2E,;IWNH (B(#YL "21#]Y-%LF(=?AD03 Q^H#^^-W/2?"[0,
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M# 8# 8# 8# 8# 8# 8# 8# P.>-Y_OSX.GZ6G3?X$.0.!+/ 8# 8# 8# 8#
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M7!&[@[;T@M3.$B0!4UA;'6,8@F 1*)A[<OCOZ(F)UJZQ;CGZIU?-]5OX:?S
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M'C- 7ZI9$I3N"K%,40F9;^4O)>D3O(?24YLZBR.TZ-R0XW:TH]VB],G6L,W
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MXD;3JLNK-)\YN+''6+H<)JUT,]:Z!R.C=<IO2SUSEK X?1UAK*]_3=HOF:!
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ME8J.I:"< "<6V2:J)MBJ'4%<QNA "_LCP?X=R9[0M)\;-2/UKL_K4M;G3NM
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8C$1&TS+M9"#:336:=LP+W44D@!<P?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g423556g33s03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g423556g33s03.jpg
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M>'!A8VME="!E;F0](G(B/S[_[0!(4&AO=&]S:&]P(#,N,  X0DE-! 0
M  \< 5H  QLE1QP"   "  ( .$))300E       0_.$?B<BWR7@O-&(T!UAW
MZ__N  Y!9&]B90!DP     '_VP"$  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,# P,# P,! 0$!
M 0$! @$! @(" 0(" P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# __  !$( "@!"0,!$0 "$0$#$0'_Q #    !! ,!
M 0$            )!@<("@ $!0$" P$  00# 0$             !@,%!P@
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M^5SJWEXW996M!,E?3.JFD<22?U::0^_#[R46;*>28S$&;JW"0T_9'*T96;-
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M<OS$16(L!S$]PJJ:G8 @;0O>/V]ZA^OMFDA/2#7M)WWSBSYRG!^XRO.:>?\
M*4IR86RZ3(3F)E*C(R\9") >3SD1FC!M@Q&TQ5?9"G-K#!VUS-(L64.[!^XC
MWT,DT65-)1STY!03<J '8)0'N'??IIOQ.VT5P#HJT[BGA$C>I[N;EV U=K1C
M-3],W5-K*P$[B2E8 $_$&)>1G(!#''#>GY\R2]<SS]+%54GY0P?;-G]GL\U'
MLDV;%#VR)-4W<M+.2D'M(!4RB)NWM+MIE=M_GW9RWL"2?,E[!$OT?<1&/]H:
M7.\@67'Q;VW5Z2*W%"03/J3I[! ?JYGKR)\N[%8Y3$$I-Q,-"+>XXB:6X@JK
M6( JW>JQBSS<UVNY:540+W;'744. =W:0H@&C-=LQRS(2W734^H:SBFM!W#]
M0_=VXU-PQ N-6YATCRV5I;;:&I3-2A^(LCD##I\:N?&=<<9D9X2Y2JNI-F^G
MFU3?2EC8,H^W4F>D#HH1BLB\CTD&LQ!.EUT@.8Q3&*FJ58BIB )3:MPQV@JZ
M)5=:>"1.7*7&##MGW^SG'LT1@G='\0K=\LN.)VNH6J6P*EQ2>'MAIO+D'_V3
M@?VX=KOX_G]NZ!^SKK=PV?Y:Y/C-0@.]7J4CN%;U(GM^B1]F[2"QY=M&:ZEP
M_P >2''V(=S637E8Q5$1;5E"(V!RBP?PS DH^28.A^S*9HV+W>\N I)>I@'I
MH+HVZ-V]N)N!E3;R3]L6WR2XYE;.T=MJ<$;+N1*I:-"!MW22IM(6J1F/A'/E
M O;BR\L%/K<ADJS6/(S6%B&JLM*(L)ZDOG$<P;$%9R[=U>)(N?[1JD03J 5$
MX$( B(; .C!E6).N_3-)3.<@3S]G6*L7Q'JNL]O<R*XOU0I6P5J2E25;4IXD
MH'!$HGGX[N8]KY(1-JH^2RLW.0*,SCY5*?CFB3%&S5M\J=D#MVR;]K9O+L'I
M"D5%$I452*D,!"CW (YDED;M;B7F/Z#D3]Z=>\]Q[DT%1:LA"57VD2%S2-J7
M&B=LY:?$#*>FIB _F (!^0%!(([%-B!J03?(!MEE 1_@ Z)L+^&@<5RWQ7/U
MCJ*,]MRTS)%!I_VU?<(^/U?Y+,@XQA<C4)I;ZABBKU:)95V+IZD'%.WL!7HQ
MNQ+-(1;\5+190<)-!6.MVB10!'VD^SM#2?EXNS5+8J?CJ5+.OB>4;B[OZEKW
MBS&161+U'C=)3("&V=J2IMM 3YDE?$N83,^^)8^.KG'=,S3LEAG+[U"9MB,.
MO.4^W T08OIQG&^V65AYE!H1NU5DF:2H+I+D33,JD50#@)B@8S3DN/-V]L5U
M)+R%2TZ \XECTX]\[WF]8YA>9[3=VT%;;H,E*0DZI<Z*' *Y\(83E/S7Y)7+
MD-,8&X]OI"MMH.S*4>,:UII'*VJW65D'M2;A:4D4G!&#!!R50J9$_:*1)(5%
M#CO]+A:;%;&+<+E<Y*01XZ0 =U.]W<:[]P'< [>E5.AA_P D!'Q/+>'$$Z23
M*9&L:S:#\N&/WD?++/[W8F1G355XR3EZ+>4C-1<I N1U%B+EWVF1,;<$@[@
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MC/I!Q?%_@NBTC"3'*\;)1=GNN3T?>F9E@(J?IU@Q=*)(TA'O JK5>.<)B=\
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M5GF&R-?\0(#1$K2?(_(?&?%Y#K*GC*]2L2F%4#"1)DVLTS)2;A,1ZBBA#/\
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M552R"&G%I!Z&4,]PQJPW5P.W&CI7G4\%.-(61[U QW8J!B()BE%P<7%PL:W
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(90\;W>L?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g423556g48s04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g423556g48s04.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X008:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM<#I#<F5A
M=&]R5&]O;#TB4%-C<FEP=#4N9&QL(%9E<G-I;VX@-2XR+C(B('AM<$U-.DEN
M<W1A;F-E240](GAM<"YI:60Z044W0D8Q0C,V-S<S,3%%1#E"0T-$130V1# S
M0D,P0T$B('AM<$U-.D1O8W5M96YT240](GAM<"YD:60Z044W0D8Q0C0V-S<S
M,3%%1#E"0T-$130V1# S0D,P0T$B/B \9&,Z8W)E871O<CX@/')D9CI397$^
M(#QR9&8Z;&D^<G(Q-S8S-C(\+W)D9CIL:3X@/"]R9&8Z4V5Q/B \+V1C.F-R
M96%T;W(^(#QD8SIT:71L93X@/')D9CI!;'0^(#QR9&8Z;&D@>&UL.FQA;F<]
M(G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@+2!&+3%?3F]V96UB97)?,C R
M,E]025!%/"]R9&8Z;&D^(#PO<F1F.D%L=#X@/"]D8SIT:71L93X@/'AM<$U-
M.D1E<FEV961&<F]M('-T4F5F.FEN<W1A;F-E240](GAM<"YI:60Z044W0D8Q
M0C$V-S<S,3%%1#E"0T-$130V1# S0D,P0T$B('-T4F5F.F1O8W5M96YT240]
M(GAM<"YD:60Z044W0D8Q0C(V-S<S,3%%1#E"0T-$130V1# S0D,P0T$B+SX@
M/"]R9&8Z1&5S8W)I<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^(#P_
M>'!A8VME="!E;F0](G(B/S[_[0!(4&AO=&]S:&]P(#,N,  X0DE-! 0
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M_E#[/T*M?,?XH>Q_(_EN_1_6'S'\1]-]CV?#W.!.=']T3_R'EY?[?LX#G .
,< X!P#@' . <#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
